

Data Set Name: adverseevent.sas7bdat

Num	Variable	Type	Len	Label
1	ReportType	Char	9	AE Report Type
2	Eventabateafterstoppingdrug	Char	14	Did the eventreaction abate after stopping drug
3	EventReappearAfterReintro	Char	14	Did the eventreaction reappear after reintroduction
4	AEPrimarySecondary1	Char	9	Is this event a primary or secondary event
5	Details	Char	3985	Adverse Event Details
6	TreatmentLocationOther	Char	108	AE Treatment Location Other
7	Comments	Char	3025	Comments
8	ElectronicSignature	Char	1	Electronic Signature
9	Category	Char	35	Category
10	CausalityByReporter	Char	22	Causality by reporter
11	ReasonForFollowup	Char	55	AE Reason for followup
12	TreatmentLocation	Char	14	Adverse Event Treatment Location
13	AEEExpected1	Char	3	Expected
14	AEPatientOutcome1	Char	35	Patient Outcome
15	FollowUpInstanceNumber	Num	8	AE Followup instance number
16	InitialAEID	Num	8	AE Initial AEID
17	Other	Num	8	Adverse Event Other
18	PrimaryAEID	Num	8	If this is a secondary event please enter primary adverse event ID
19	ReporterStaffCode	Num	8	AE Reporter Staff Code
20	SelectTerm	Num	8	AE Select Term
21	SupraOrdinateTerm	Num	8	Adverse Event SupraOrdinate Term sub category
22	Assoc_Death	Num	8	AEAssociations: Death
23	Assoc_DevBirthDefect	Num	8	AEAssociations: Development of a congenital anomaly or birth defect
24	Assoc_DevPermntSeriousCondition	Num	8	AEAssociations: Development of a permanent/ serious/ disabling /incapacitating condition
25	Assoc_Hospital_ProlongedHospital	Num	8	AEAssociations: Hospitalization or prolonged hospitalization
26	Assoc_AnotherCondnRepSHazards	Num	8	AEAssociations: Is another condition which investigators judge to represent significant hazards
27	Assoc_Lifethreatening	Num	8	AEAssociations: Life threatening
28	severity_index	Num	8	AE Grade per the CTCAE
29	Serious	Char	10	Serious
30	AEID	Num	8	
31	MaskID	Num	8	Participant Mask ID#
32	Visit	Char	100	Visit
33	Date_of_Visit	Num	8	Date of Visit
34	Date_at_Death	Num	8	Date at Death
35	Date_at_FollowUp	Num	8	Date at Follow-Up
36	Date_at_Occurence	Num	8	Date at Occurence

Num	Variable	Type	Len	Label
37	Date_at_Report	Num	8	Date at Report
38	Date_Resolved	Num	8	Date Resolved
39	Date_Study_Drug_Started1	Num	8	Date Study Drug Started #1
40	Date_Study_Drug_Started2	Num	8	Date Study Drug Started #2
41	Date_Study_Drug_Started3	Num	8	Date Study Drug Started #3
42	Date_Study_Drug_Started4	Num	8	Date Study Drug Started #4
43	Date_Study_Drug_Started5	Num	8	Date Study Drug Started #5
44	Date_Study_Drug_Stopped1	Num	8	Date Study Drug Stopped #1
45	Date_Study_Drug_Stopped2	Num	8	Date Study Drug Stopped #2
46	Date_Study_Drug_Stopped3	Num	8	Date Study Drug Stopped #3
47	Date_Study_Drug_Stopped4	Num	8	Date Study Drug Stopped #4
48	Date_Study_Drug_Stopped5	Num	8	Date Study Drug Stopped #5

Data Set Name: adverseevent.sas7bdat

Num	Variable	Type	Len	Label
1	ReportType	Char	9	AE Report Type
2	Eventabateafterstoppingdrug	Char	14	Did the eventreaction abate after stopping drug
3	EventReappearAfterReintro	Char	14	Did the eventreaction reappear after reintroduction
4	AEPrimarySecondary1	Char	9	Is this event a primary or secondary event
5	Details	Char	3985	Adverse Event Details
6	TreatmentLocationOther	Char	108	AE Treatment Location Other
7	Comments	Char	3025	Comments
8	ElectronicSignature	Char	1	Electronic Signature
9	Category	Char	35	Category
10	CausalityByReporter	Char	22	Causality by reporter
11	ReasonForFollowup	Char	55	AE Reason for followup
12	TreatmentLocation	Char	14	Adverse Event Treatment Location
13	AEEExpected1	Char	3	Expected
14	AEPatientOutcome1	Char	35	Patient Outcome
15	FollowUpInstanceNumber	Num	8	AE Followup instance number
16	InitialAEID	Num	8	AE Initial AEID
17	Other	Num	8	Adverse Event Other
18	PrimaryAEID	Num	8	If this is a secondary event please enter primary adverse event ID
19	ReporterStaffCode	Num	8	AE Reporter Staff Code
20	SelectTerm	Num	8	AE Select Term
21	SupraOrdinateTerm	Num	8	Adverse Event SupraOrdinate Term sub category
22	Assoc_Death	Num	8	AEAssociations: Death
23	Assoc_DevBirthDefect	Num	8	AEAssociations: Development of a congenital anomaly or birth defect
24	Assoc_DevPermntSeriousCondition	Num	8	AEAssociations: Development of a permanent/ serious/ disabling /incapacitating condition
25	Assoc_Hospital_ProlongedHospital	Num	8	AEAssociations: Hospitalization or prolonged hospitalization
26	Assoc_AnotherCondnRepSHazards	Num	8	AEAssociations: Is another condition which investigators judge to represent significant hazards
27	Assoc_Lifethreatening	Num	8	AEAssociations: Life threatening
28	severity_index	Num	8	
29	Serious	Char	10	Serious
30	AEID	Num	8	
31	MaskID	Num	8	Participant Mask ID#
32	Visit	Char	100	Visit
33	Date_of_Visit	Num	8	Date of Visit
34	Date_at_Death	Num	8	Date at Death
35	Date_at_FollowUp	Num	8	Date at Follow-Up

Num	Variable	Type	Len	Label
36	Date_at_Occurence	Num	8	Date at Occurence
37	Date_at_Report	Num	8	Date at Report
38	Date_Resolved	Num	8	Date Resolved
39	Date_Study_Drug_Started1	Num	8	Date Study Drug Started #1
40	Date_Study_Drug_Started2	Num	8	Date Study Drug Started #2
41	Date_Study_Drug_Started3	Num	8	Date Study Drug Started #3
42	Date_Study_Drug_Started4	Num	8	Date Study Drug Started #4
43	Date_Study_Drug_Started5	Num	8	Date Study Drug Started #5
44	Date_Study_Drug_Stopped1	Num	8	Date Study Drug Stopped #1
45	Date_Study_Drug_Stopped2	Num	8	Date Study Drug Stopped #2
46	Date_Study_Drug_Stopped3	Num	8	Date Study Drug Stopped #3
47	Date_Study_Drug_Stopped4	Num	8	Date Study Drug Stopped #4
48	Date_Study_Drug_Stopped5	Num	8	Date Study Drug Stopped #5

Data Set Name: aereview.sas7bdat

Num	Variable	Type	Len	Label
1	AEAdditionalInfoRequested	Char	3	AE Additional information requested
2	AEReviewPriorSimilarSAEs	Char	3	AE Review Have there been prior occurrences of similar SAEs reported in this study
3	AEReviewReportingTimeframe	Char	27	AE Review Reporting time frame to regulatory authorities
4	AEReviewTreatmentUnblindedForC	Char	2	AE Review Does treatment need to be unblinded for determination of causality
5	AEAdditionalInfoRequestedDetail	Char	499	AE Additional information requested details
6	AEReviewDSMBReviewComments	Char	1	AE Review Requires DSMB Review Comments
7	AEReviewFormComments	Char	341	Adverse Event Review Form Comments
8	AEReviewPriorSimilarSAEsSummar	Char	220	AE Review If prior occurrences of similar SAEs provide brief summary
9	AECausalityByReviewer	Char	22	Causality by reviewer
10	AEPatientOutcome	Char	1	Patient Outcome
11	RecommendConsentChange	Char	3	Recommend changes to the consent form
12	RecommendProtocolChange	Char	2	Recommend changes to the protocol
13	AEReviewRequireDSMBReview	Num	8	AE Review Requires urgent and immediate review by full DSMB committee
14	AEID	Num	8	AEID
15	MaskID	Num	8	Participant Mask ID#
16	Visit	Char	100	Visit
17	Date_of_Visit	Num	8	Date of Visit

Data Set Name: followup_eligible_participant.sas7bdat

Num	Variable	Type	Len	Label
1	BiweeklyInjectionVisitSchedule	Char	16	Biweekly Injection Visit Schedule
2	ConcernsAboutReceivingPlaceboR	Char	20	Concerns about receiving placebo Rank
3	ConflictingResponsibilitiesRan	Char	20	Conflicting Responsibilities Rank
4	DoesNotTolerateOGTTTRank	Char	20	Does not tolerate OGTTIVGTTs well Rank
5	DoesNotWantToBeBlindedRank	Char	16	Does not want to be blinded to individual test results during the study Rank
6	FamilyWishesToWaitUntilOlderRa	Char	20	Family wishes to wait until participant is older Rank
7	FearOfStudyDrugRisksRank	Char	20	Fear of Study Drug Risks Rank
8	IndicateTheStudyParticipantWas	Char	31	Please indicate which TrialNet Study this participant was offered
9	IsParticipantCurrentlyEligible	Char	20	If participant was offered an intervention study please indicate if participant is currently eligible or potentially eligible
10	IsTheParticipantInterested	Char	8	Is the participant interested in participating in the above study
11	LostToFollowUp	Char	16	Lost to FollowUp
12	MonetaryCompensationRank	Char	16	Monetary Compensation Rank
13	MonthlyInfusionVisitScheduleRa	Char	20	Monthly Infusion Visit Schedule Rank
14	OtherRank	Char	20	Other Rank
15	PregnantNursingOrPlanningChild	Char	16	Pregnant nursing or planning children in the future Rank
16	TimeCommitmentRank	Char	20	Time Commitment Rank
17	UnableUnwillingToTravelRank	Char	20	Unable Unwilling to Travel Rank
18	UnwillingToTakeInvestigational	Char	20	Unwilling to take investigational drug Rank
19	_2DayInfusionPeriod	Char	1	2 Day Infusion Period
20	_2WeekIfusionPeriodRank	Char	20	2 week Infusion Period Rank
21	willingToConsiderAtALaterTime	Char	3	Did the participant indicate they may be willing to consider participating in the study at a later time
22	AdditionalComments	Char	948	Additional comments describing participants Situation
23	ParticipantWasContactedByOther	Char	49	Participant was contacted by Other Specify
24	ReasonsNotInterestedOtherSpeci	Char	1289	Reasons the participant is not currently interested Other Specify
25	ParticipantWasContac_AffiliateS1	Num	8	ParticipantWasContac: Affiliate Site Coordinator
26	ParticipantWasContac_AffiliateS2	Num	8	ParticipantWasContac: Affiliate Site PI
27	ParticipantWasContac_ClinicalCe1	Num	8	ParticipantWasContac: Clinical Center Coordinator
28	ParticipantWasContac_ClinicalCe2	Num	8	ParticipantWasContac: Clinical Center PI
29	ParticipantWasContac_Other	Num	8	ParticipantWasContac: Other
30	ReasonsNotInterested_2DayInfusio	Num	8	ReasonsNotInterested: 2 Day Infusion Period
31	ReasonsNotInterested_2weekInfusi	Num	8	ReasonsNotInterested: 2 week Infusion Period
32	ReasonsNotInterested_BiweeklyInj	Num	8	ReasonsNotInterested: Biweekly Injection Visit Schedule
33	ReasonsNotInterested_Concernsabo	Num	8	ReasonsNotInterested: Concerns about receiving placebo
34	ReasonsNotInterested_Conflicting	Num	8	ReasonsNotInterested: Conflicting Responsibilities (Work, School, Family)

Num	Variable	Type	Len	Label
35	ReasonsNotInterested_Doesnotwant	Num	8	ReasonsNotInterested: Does not want to be blinded to individual test results during the study
36	ReasonsNotInterested_Familywishe	Num	8	ReasonsNotInterested: Family wishes to wait until participant is older
37	ReasonsNotInterested_FearofStudy	Num	8	ReasonsNotInterested: Fear of Study Drug Risks
38	ReasonsNotInterested_LosttoFollo	Num	8	ReasonsNotInterested: Lost to Follow-Up
39	ReasonsNotInterested_MonetaryCom	Num	8	ReasonsNotInterested: Monetary Compensation
40	ReasonsNotInterested_MonthlyInfu	Num	8	ReasonsNotInterested: Monthly Infusion Visit Schedule
41	ReasonsNotInterested_Other	Num	8	ReasonsNotInterested: Other
42	ReasonsNotInterested_Participant	Num	8	ReasonsNotInterested: Participant does not tolerate OGTT/IVGTTs well
43	ReasonsNotInterested_Pregnantnur	Num	8	ReasonsNotInterested: Pregnant, nursing or planning children in the future
44	ReasonsNotInterested_Refusednore	Num	8	ReasonsNotInterested: Refused; no reason given
45	ReasonsNotInterested_TimeCommitm	Num	8	ReasonsNotInterested: Time Commitment
46	ReasonsNotInterested_UnableUnwil	Num	8	ReasonsNotInterested: Unable/ Unwilling to Travel
47	ReasonsNotInterested_Unwillingto	Num	8	ReasonsNotInterested: Unwilling to take investigational drug
48	MaskID	Num	8	Participant Mask ID#
49	Visit	Char	100	Visit
50	Date_of_Visit	Num	8	Date of Visit

Data Set Name: nh01_screeningform.sas7bdat

Num	Variable	Type	Len	Label
1	BloodSamplesFutureTestingPermi	Char	7	Did participant give permission for remaining blood samples to be stores for future testing as described in the informed consent form
2	BloodTestForFindOut	Char	73	This blood test is being done to find out if
3	CommunicationWhenNegAutoantibo	Char	62	If you are negative for autoantibodies we will inform you via
4	Ethnicity	Char	22	Participant Ethnicity
5	HaveDiabetes	Char	3	Do you have diabetes
6	InformedTestResultWithin	Char	9	We will let you know your test results within a duration of your blood draw
7	InitialScreeningLocation	Char	26	Where did initial screening blood draw occur
8	PermissionToControlIfTheyTestA	Char	7	Did participant give permission on the informed consent form to be a control if they test autoantibody negative
9	Relationship	Char	11	Relationship
10	RelativeWithT1D	Char	3	Do you have a relative with T1D
11	Sex	Char	6	Participant Sex
12	_15Aug2011ConsentForResidualSa	Char	7	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
13	FirstHearAboutTrialNetOthersSp	Char	96	How did you first hear about TrialNet other specify
14	InitialScreeningLocationOtherS	Char	80	Where did initial screening blood draw occur Other Specify
15	OnlineScreeningReferralSource	Char	13	Online screening referal site
16	OtherSpecify	Char	45	Participant Race other specify
17	DateSignedNEWInformedConsentFo2	Char	3	Date signed NEW informed consent form Month
18	Age	Num	8	Age
19	DateSignedNEWInformedConsentFo	Num	8	Date signed NEW informed consent form Day
20	DateSignedNEWInformedConsentFo3	Num	8	Date signed NEW informed consent form Year
21	DegreeOfRelative_1st	Num	8	DegreeOfRelative: 1st
22	DegreeOfRelative_2ndor3rd	Num	8	DegreeOfRelative: 2nd or 3rd
23	FirstHearAboutTrialN_Brochure	Num	8	FirstHearAboutTrialN: Brochure
24	FirstHearAboutTrialN_Camp	Num	8	FirstHearAboutTrialN: Camp
25	FirstHearAboutTrialN_ExistingTri	Num	8	FirstHearAboutTrialN: Existing TrialNet Site
26	FirstHearAboutTrialN_FamilyFrien	Num	8	FirstHearAboutTrialN: Family/Friend
27	FirstHearAboutTrialN_Healthcarep	Num	8	FirstHearAboutTrialN: Health care professional
28	FirstHearAboutTrialN_Internet	Num	8	FirstHearAboutTrialN: Internet
29	FirstHearAboutTrialN_MeetingPres	Num	8	FirstHearAboutTrialN: Meeting/Presentation
30	FirstHearAboutTrialN_NewspaperMa	Num	8	FirstHearAboutTrialN: Newspaper/Magazine
31	FirstHearAboutTrialN_Other	Num	8	FirstHearAboutTrialN: Other
32	FirstHearAboutTrialN_Poster	Num	8	FirstHearAboutTrialN: Poster
33	FirstHearAboutTrialN_RadioTV	Num	8	FirstHearAboutTrialN: Radio/TV
34	FirstHearAboutTrialN_Tollfreeph	Num	8	FirstHearAboutTrialN: Toll free phone number

Num	Variable	Type	Len	Label
35	Race_AmericanIndianorAlaskaNat	Num	8	Race: American Indian or Alaska Native
36	Race_Asian	Num	8	Race: Asian
37	Race_BlackorAfricanAmerican	Num	8	Race: Black or African American
38	Race_NativeHawaiianorOtherPaci	Num	8	Race: Native Hawaiian or Other Pacific Islander
39	Race_Refused	Num	8	Race: Refused
40	Race_Unknownornotreported	Num	8	Race: Unknown or not reported
41	Race_White	Num	8	Race: White
42	MaskID	Num	8	Participant Mask ID#
43	Visit	Char	100	Visit
44	Date_of_Visit	Num	8	Date of Visit
45	Date_Consent_Signed	Num	8	Date Consent Signed
46	Date_at_Screening	Num	8	Date at Screening
47	DOB_Month	Num	8	Date of Birth - Month
48	DOB_Year	Num	8	Date of Birth - Year

Data Set Name: nh01f_familyhistoryform.sas7bdat

Num	Variable	Type	Len	Label
1	SexOfRelativeWithT1D1	Char	6	Sex of Relative
2	SexOfRelativeWithT1D2	Char	6	Sex of Relative
3	SexOfRelativeWithT1D3	Char	6	Sex of Relative
4	SexOfRelativeWithT1D4	Char	6	Sex of Relative
5	SexOfRelativeWithT1D5	Char	6	Sex of Relative
6	SexOfRelativeWithT1D6	Char	6	Sex of Relative
7	SexOfRelativeWithT1D7	Char	6	Sex of Relative
8	SexOfRelativeWithT1D8	Char	6	Sex of Relative
9	SexOfRelativeWithT1D9	Char	6	Sex of Relative
10	SexOfRelativeWithT1D10	Char	4	Sex of Relative
11	RelativeComments1	Char	165	Relative Comments
12	RelativeComments2	Char	186	Relative Comments
13	RelativeComments3	Char	100	Relative Comments
14	RelativeComments4	Char	100	Relative Comments
15	RelativeComments5	Char	100	Relative Comments
16	RelativeComments6	Char	69	Relative Comments
17	RelativeComments7	Char	33	Relative Comments
18	RelativeComments8	Char	27	Relative Comments
19	RelativeComments9	Char	5	Relative Comments
20	RelativeComments10	Char	1	Relative Comments
21	RelativeWithT1D1	Char	22	Relative with Type 1 Diabetes
22	RelativeWithT1D2	Char	22	Relative with Type 1 Diabetes
23	RelativeWithT1D3	Char	22	Relative with Type 1 Diabetes
24	RelativeWithT1D4	Char	22	Relative with Type 1 Diabetes
25	RelativeWithT1D5	Char	17	Relative with Type 1 Diabetes
26	RelativeWithT1D6	Char	22	Relative with Type 1 Diabetes
27	RelativeWithT1D7	Char	17	Relative with Type 1 Diabetes
28	RelativeWithT1D8	Char	17	Relative with Type 1 Diabetes
29	RelativeWithT1D9	Char	14	Relative with Type 1 Diabetes
30	RelativeWithT1D10	Char	8	Relative with Type 1 Diabetes
31	NumOfRelativesWithT1D	Num	8	How many of the participants blood relatives have type 1 diabetes including deceased relatives
32	AgeOfOnsetInRelativeWithT1D1	Num	8	Age of Onset in Relative
33	AgeOfOnsetInRelativeWithT1D2	Num	8	Age of Onset in Relative
34	AgeOfOnsetInRelativeWithT1D3	Num	8	Age of Onset in Relative
35	AgeOfOnsetInRelativeWithT1D4	Num	8	Age of Onset in Relative
36	AgeOfOnsetInRelativeWithT1D5	Num	8	Age of Onset in Relative

Num	Variable	Type	Len	Label
37	AgeOfOnsetInRelativeWithT1D6	Num	8	Age of Onset in Relative
38	AgeOfOnsetInRelativeWithT1D7	Num	8	Age of Onset in Relative
39	AgeOfOnsetInRelativeWithT1D8	Num	8	Age of Onset in Relative
40	AgeOfOnsetInRelativeWithT1D9	Num	8	Age of Onset in Relative
41	AgeOfOnsetInRelativeWithT1D10	Num	8	Age of Onset in Relative
42	AgeOfRelativeWithT1D1	Num	8	Current Age of Relative
43	AgeOfRelativeWithT1D2	Num	8	Current Age of Relative
44	AgeOfRelativeWithT1D3	Num	8	Current Age of Relative
45	AgeOfRelativeWithT1D4	Num	8	Current Age of Relative
46	AgeOfRelativeWithT1D5	Num	8	Current Age of Relative
47	AgeOfRelativeWithT1D6	Num	8	Current Age of Relative
48	AgeOfRelativeWithT1D7	Num	8	Current Age of Relative
49	AgeOfRelativeWithT1D8	Num	8	Current Age of Relative
50	AgeOfRelativeWithT1D9	Num	8	Current Age of Relative
51	AgeOfRelativeWithT1D10	Num	8	Current Age of Relative
52	AgeRelativeWithT1DStartedIn1	Num	8	Age Relative Started Insulin
53	AgeRelativeWithT1DStartedIn2	Num	8	Age Relative Started Insulin
54	AgeRelativeWithT1DStartedIn3	Num	8	Age Relative Started Insulin
55	AgeRelativeWithT1DStartedIn4	Num	8	Age Relative Started Insulin
56	AgeRelativeWithT1DStartedIn5	Num	8	Age Relative Started Insulin
57	AgeRelativeWithT1DStartedIn6	Num	8	Age Relative Started Insulin
58	AgeRelativeWithT1DStartedIn7	Num	8	Age Relative Started Insulin
59	AgeRelativeWithT1DStartedIn8	Num	8	Age Relative Started Insulin
60	AgeRelativeWithT1DStartedIn9	Num	8	Age Relative Started Insulin
61	AgeRelativeWithT1DStartedIn10	Num	8	Age Relative Started Insulin
62	MaskID	Num	8	Participant Mask ID#
63	Visit	Char	100	Visit
64	Date_of_Visit	Num	8	Date of Visit

Data Set Name: nh04_baselinriskassessment.sas7bdat

Num	Variable	Type	Len	Label
1	AddisonsDiseaseEver	Char	3	Addisons Disease ever
2	AddisonsDiseaseWithinLastYear	Char	3	Addisons Disease Within the last year
3	AllergiesEver	Char	3	Allergies Ever
4	AllergiesWithinLastYear	Char	3	Allergies Within last year
5	AlopeciaEver	Char	3	Alopecia Hair Loss Ever
6	AlopeciaWithinLastYear	Char	3	Alopecia Hair Loss Within the last year
7	AntibodySampleCollected	Char	3	Antibodies sample collected
8	AsthmaEver	Char	3	Asthma ever
9	AsthmaWithinLastYear	Char	3	Asthma within last year
10	BetaBlockers	Char	3	Currently taking any medications Beta Blockers
11	BllodForDNASampleCollected	Char	3	Sample Whole Blood for DNA Sample Collecetd
12	BloodForCellsSampleCollected	Char	3	Sample Whole Blood for cells Sample Collected
13	BloodForRNASampleCollected	Char	3	Sample Whole Blood for RNA Sample Collected
14	CancerEver	Char	3	Cancer Ever
15	CancerWithinLastYear	Char	3	Cancer Within the last year
16	CeliacDiseaseEver	Char	3	Celiac Disease ever
17	CeliacDiseaseWithinLastYear	Char	3	Celiac Disease Within the last year
18	ColitisOrColonProblemsEver	Char	3	Colitis or colon problems ever
19	ColitisOrColonProblemsWithinLa	Char	3	Colitis or colon problems Within the last year
20	CongenitalHeartDiseaseEver	Char	3	Congenital heart disease or heart problems ever
21	CongenitalHeartDiseaseWithinLa	Char	3	Congenital heart disease or heart problems Within the last year
22	ConsenToContinuedStorageOfBloo	Char	14	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
23	Corticosteroids	Char	3	Currently taking any medications Corticosteroids ie prednisone
24	Diphenylhydantoin	Char	3	Currently taking any medications Diphenylhydantoin
25	EpilepsyConvulsionsSeizuresEve	Char	3	Epilepsy convulsions or seizures ever
26	EpilepsyConvulsionsSeizuresWit	Char	3	Epilepsy convulsions or seizures Within the last year
27	EverParticipatedInPreventionSt	Char	3	Has the participant ever participated ina prevention study for T1D
28	HLASamplesCollected	Char	3	HLA sample collected
29	HbA1cSamplesCollected	Char	3	HbA1c sample collected
30	HepatitisOrLiverDiseaseEver	Char	3	HepatitisLiver disease ever
31	HepatitisOrLiverDiseaseWithinL	Char	3	HepatitisLiver disease Within the last year
32	HighBPever	Char	3	High blood pressure ever
33	HighBPwithinLastYear	Char	3	High blood pressure within last year
34	HighCholestrolEver	Char	3	High Cholestrol ever
35	HighCholestrolWithinLastYear	Char	3	High cholestrol within last year
36	IVGTTSampleCollected	Char	3	IVGTT sample collected

Num	Variable	Type	Len	Label
37	ImmunosuppressiveTherapies	Char	3	Currently taking any medications Immunosuppressives or immunomodulatory therapies
38	InfectiousMononucleosisEver	Char	3	Infectious mononucleosis ever
39	InfectiousMononucleosisWithinL	Char	3	Infectious mononucleosis Within the last year
40	InflammatoryValveDiseaseEver	Char	3	Inflammatory Valve Disease ever
41	InflammatoryValveDiseaseWithin	Char	3	Inflammatory Valve Disease within last year
42	MultipleSclerosisEver	Char	3	Multiple Sclerosis ever
43	MultipleSclerosisWithinLastYea	Char	3	Multiple Sclerosis within last year
44	Niacin	Char	3	Currently taking any medications Niacin
45	OGTTSampleCollected	Char	3	OGTT sample collected
46	OtherAutoimmuneDiseasesEver	Char	3	Other autoimmune diseases ever
47	OtherAutoimmuneDiseasesWithinL	Char	3	Other autoimmune diseases within last year
48	ParticipantDiagnosedWithT1D	Char	3	Has the participant been diagnosed with type 1 diabetes T1D
49	ParticipantHasKnownSevereActiv	Char	3	Does the participant have known severe inactive diseases and/or diseases which are likely to limit life expectancy or lead to use of immunosuppressive or immunomodulatory therapies during the course of the study
50	ParticipantHasOneRelativeWithT	Char	3	Does the participant have at least one blood relative living or deceased with type 1 diabetes T1D
51	ParticipantPregnant	Char	14	For females of child bearing age/potential is the participant currently pregnant
52	ParticipantUsedInsulinOrOtherG	Char	3	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alpha-glucosidase inhibitors meglitinides GLP1 mimetics and
53	ParticipantUsingImmunosuppressi	Char	3	Is the participant currently using immunosuppressive or immunomodulatory therapies or systemic glucocorticoids
54	ParticipateInDPT1	Char	3	Did the participant participate in DPT1
55	PermissionForHLAgeneticTesting	Char	3	Permission for his/her blood to be tested for HLA genes
56	PermissionForSampleStorage	Char	3	Storage of his/her samples for future testing
57	PerniciousAnemiaEver	Char	3	Pernicious anemia ever
58	PerniciousAnemiaWithinLastYear	Char	3	Pernicious anemia Within the last year
59	PlasmaSampleCollected	Char	3	Sample Plasma Sample Collected
60	PotassiumDepletingDiurectics	Char	3	Currently taking any medications Potassium Depleting Diurectics
61	PsoriasisEver	Char	3	Psoriasis ever
62	PsoriasisWithinLastYear	Char	3	Psoriasis Within the last year
63	RheumatologicEver	Char	3	Rheumatologic disease Ever
64	RheumatologicWithinLastYear	Char	3	Rheumatologic disease Within the last year
65	SerumForProteomicsSampleCollec	Char	3	Sample Serum for Proteomics sample collected
66	ThyroidDiseaseEver	Char	3	Thyroid disease ever
67	ThyroidDiseaseWithinLastYear	Char	3	Thyroid disease Within the last year
68	UlcerEver	Char	3	Ulcer stomach or duodenal ever
69	UlcerWithinLastYear	Char	3	Ulcer stomach or duodenal Within the last year

Num	Variable	Type	Len	Label
70	VitiligoEver	Char	3	Vitiligo ever
71	VitiligoWithinLastYear	Char	3	Vitiligo Within the last year
72	Antibodycomment	Char	79	Antibodies Comment
73	BetaBlockersSpecify	Char	43	Currently taking any medications Beta Blockers If YES specify
74	BllodForDNAComment	Char	100	Sample Whole Blood for DNA Comment
75	BloodForCellsComment	Char	133	Sample Whole Blood for cells Comment
76	BloodForRNAComment	Char	133	Sample Whole Blood for RNA comment
77	DPT1ParticipantIDNumber	Char	30	Did the participant participate in DPT1 if Yes record the DPT1 participant ID number
78	HLAComment	Char	183	HLA comment
79	HbA1cComment	Char	79	HbA1c comment
80	IVGTTComment	Char	80	IVGTT Comment
81	ImmunosuppressiveTherapiesSpec	Char	25	Currently taking any medications Immunosuppressives or immunomodulatory therapies If YES specify
82	OGTTComment	Char	153	OGTT comment
83	OtherAutoimmuneDiseasesSpecify	Char	78	Other autoimmune diseases specify
84	ParticipantUsedInsulinOrOtherG2	Char	93	If yes specify
85	PlasmaComment	Char	133	Sample Plasma Comment
86	PotassiumDepletingDiurecticsSp	Char	22	Currently taking any medications Potassium Depleting Diurectics If YES specify
87	SerumForProteomicsComment	Char	133	Sample Serum for Proteomics Comment
88	SpecifyStudyForPreventionOfT1D	Char	54	Has the participant ever participated in a prevention study for T1D If Yes name of studystudies
89	SteroidsSpecify	Char	90	Currently taking any medications Steroids if YES specify
90	YESSpecify	Char	334	If YES specify
91	DateSignedNEWInformedConsentFo2	Char	3	Date signed NEW informed consent form Month
92	DateSignedNEWInformedConsentFo	Num	8	Date signed NEW informed consent form Day
93	DateSignedNEWInformedConsentFo3	Num	8	Date signed NEW informed consent form Year
94	Heightcm	Num	8	Collect the following assessments Height in cm
95	Heightin	Num	8	Collect the following assessments Height in inches
96	SeatedArmBPDiastolic	Num	8	Collect the following assessments Seated arm blood pressure Diastolic
97	SeatedArmBPSystolic	Num	8	Collect the following assessments Seated arm blood pressure systolic
98	SeatedHeartRate	Num	8	Collect the following assessments Seated heart rate
99	SeatedRespiratoryRate	Num	8	Collect the following assessments Seated respiratory rate
100	Weightkg	Num	8	Collect the following assessments Weight in kgs
101	Weightlbs	Num	8	Collect the following assessments Weight in lbs
102	MaskID	Num	8	Participant Mask ID#
103	Visit	Char	100	Visit
104	Date_of_Visit	Num	8	Date of Visit
105	Date_Consent_Signed	Num	8	Date Consent Signed

Num	Variable	Type	Len	Label
106	Date_Mechanistic_Sample_Coll	Num	8	Date Mechanistic Sample Collected
107	Date_Samples_Collected	Num	8	Date Samples Collected

Data Set Name: nh05_followupriskassessphase3.sas7bdat

Num	Variable	Type	Len	Label
1	AddisonsDiseaseWithinLastYear	Char	3	Addisons Disease Within the last year
2	AllergiesWithinLastYear	Char	3	Allergies Within last year
3	AlopeciaWithinLastYear	Char	3	Alopecia Hair Loss Within the last year
4	AlphaGlucosidaseInhibitors	Char	3	Alphaglucosidase inhibitors
5	AntibodySampleCollected	Char	3	Antibodies sample collected
6	AsthmaWithinLastYear	Char	3	Asthma within last year
7	BetaBlockers	Char	3	Currently taking any medications Beta Blockers
8	BllodForDNASampleCollected	Char	3	Sample Whole Blood for DNA Sample Collecetd
9	BloodForCellsSampleCollected	Char	3	Sample Whole Blood for cells Sample Collected
10	BloodForRNASampleCollected	Char	3	Sample Whole Blood for RNA Sample Collected
11	CancerWithinLastYear	Char	3	Cancer Within the last year
12	CeliacDiseaseWithinLastYear	Char	3	Celiac Disease Within the last year
13	ColitisOrColonProblemsWithinLa	Char	3	Colitis or colon problems Within the last year
14	CongenitalHeartDiseaseWithinLa	Char	3	Congenital heart disease or heart problems Within the last year
15	ConsenToContinuedStorageOfBloo	Char	14	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
16	Corticosteroids	Char	3	Currently taking any medications Corticosteroids ie prednisone
17	Diphenylhydantoin	Char	3	Currently taking any medications Diphenylhydantoin
18	EpilepsyConvulsionsSeizuresWit	Char	3	Epilepsy convulsions or seizures Within the last year
19	HbA1cSamplesCollected	Char	3	HbA1c sample collected
20	HepatitisOrLiverDiseaseWithinL	Char	3	HepatitisLiver disease Within the last year
21	HighBPwithinLastYear	Char	3	High blood pressure within last year
22	HighCholestrolWithinLastYear	Char	3	High cholestrol within last year
23	ImmunosuppressiveTherapies	Char	3	Currently taking any medications Immunosuppressives or immunomodulatory therapies
24	InfectiousMononucleosisWithinL	Char	3	Infectious mononucleosis Within the last year
25	InflammatoryValveDiseaseWithin	Char	3	Inflammatory Valve Disease within last year
26	LimitedLifeExpectancyOrImmunos	Char	3	Diseases likely to limit life expectancy or lead to use of immunosuppressiveimmunomodulatory therapies within the last year
27	Meglinitides	Char	3	Meglinitides
28	Metformin	Char	3	Metformin
29	MultipleSclerosisWithinLastYea	Char	3	Multiple Sclerosis within last year
30	Niacin	Char	3	Currently taking any medications Niacin
31	OGTTSampleCollected	Char	3	OGTT sample collected
32	OtherAutoimmuneDiseasesWithinL	Char	3	Other autoimmune diseases within last year
33	OtherGlucoseLoweringAgents	Char	3	Other glucose lowering agents
34	ParticipantDiagnosedWithT1D	Char	3	Has the participant been diagnosed with type 1 diabetes T1D

Num	Variable	Type	Len	Label
35	ParticipantPregnant	Char	14	For females of child bearing age potential is the participant currently pregnant
36	ParticipantUsedInsulinOrOtherG	Char	3	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alphaglucoSIDase inhibitors meglitinides GLP1 mimetics and
37	PermissionForSampleStorage	Char	3	Storage of hisher samples for future testing
38	PerniciousAnemiaWithinLastYear	Char	3	Pernicious anemia Within the last year
39	PlasmaSampleCollected	Char	3	Sample Plasma Sample Collected
40	PotassiumDepletingDiurectics	Char	3	Currently taking any medications Potassium Depleting Diurectics
41	PsoriasisWithinLastYear	Char	3	Psoriasis Within the last year
42	RheumatologicWithinLastYear	Char	3	Rheumatologic disease Within the last year
43	SerumForProteomicsSampleCollec	Char	3	Sample Serum for Proteomics sample collected
44	SerumMechanisticSerumSampleCol	Char	3	Sample Serum Mechanistic Serum Sample Collected
45	SignedMonitoringConsentProtoco	Char	3	Did this participant previously sign a monitoring consent form for protocol version 15Aug11
46	Thiazolidinediones	Char	3	Thiazolidinediones
47	ThyroidDiseaseWithinLastYear	Char	3	Thyroid disease Within the last year
48	UlcerWithinLastYear	Char	3	Ulcer stomach or duodenal Within the last year
49	VitiligoWithinLastYear	Char	3	Vitiligo Within the last year
50	WholeBloodPBMCPlasmaSampleColl	Char	3	Sample Whole Blood PBMCPlasma Sample Collected
51	Antibodycomment	Char	132	Antibodies Comment
52	BetaBlockersSpecify	Char	27	Currently taking any medications Beta Blockers If YES specify
53	BllodForDNAComment	Char	120	Sample Whole Blood for DNA Comment
54	BloodForCellsComment	Char	144	Sample Whole Blood for cells Comment
55	BloodForRNAComment	Char	158	Sample Whole Blood for RNA comment
56	HbA1cComment	Char	147	HbA1c comment
57	ImmunosuppressiveTherapiesSpec	Char	25	Currently taking any medications Immunosuppressives or immunomodulatory therapies If YES specify
58	OGTTComment	Char	129	OGTT comment
59	OtherAutoimmuneDiseasesSpecify	Char	67	Other autoimmune diseases specify
60	PlasmaComment	Char	120	Sample Plasma Comment
61	PotassiumDepletingDiurecticsSp	Char	53	Currently taking any medications Potassium Depleting Diurectics If YES specify
62	SerumForProteomicsComment	Char	120	Sample Serum for Proteomics Comment
63	SerumMechanisticSerumComment	Char	34	Sample Serum Mechanistic Serum comment
64	SteroidsSpecify	Char	190	Currently taking any medications Steroids if YES specify
65	WholeBloodPBMCPlasmaComment	Char	83	Sample Whole Blood PBMCPlasma comment
66	YESSpecify	Char	303	If YES specify
67	DateSignedNEWInformedConsentFo2	Char	3	Date signed NEW informed consent form Month
68	DateSignedNEWInformedConsentFo	Num	8	Date signed NEW informed consent form Day
69	DateSignedNEWInformedConsentFo3	Num	8	Date signed NEW informed consent form Year

Num	Variable	Type	Len	Label
70	Heightcm	Num	8	Collect the following assessments Height in cm
71	Heightin	Num	8	Collect the following assessments Height in inches
72	SeatedArmBPDiastolic	Num	8	Collect the following assessments Seated arm blood pressure Diastolic
73	SeatedArmBPSystolic	Num	8	Collect the following assessments Seated arm blood pressure systolic
74	SeatedHeartRate	Num	8	Collect the following assessments Seated heart rate
75	SeatedRespiratoryRate	Num	8	Collect the following assessments Seated respiratory rate
76	Weightkg	Num	8	Collect the following assessments Weight in kgs
77	Weightlbs	Num	8	Collect the following assessments Weight in lbs
78	MaskID	Num	8	Participant Mask ID#
79	Visit	Char	100	Visit
80	Date_of_Visit	Num	8	Date of Visit
81	Date_Consent_Signed	Num	8	Date Consent Signed
82	Date_Mechanistic_Sample_Coll	Num	8	Date Mechanistic Sample Collected
83	Date_Samples_Collected	Num	8	Date Samples Collected

Data Set Name: nh05c_followupriskassessment.sas7bdat

Num	Variable	Type	Len	Label
1	AddisonsDiseaseWithinLastYear	Char	2	Addisons Disease Within the last year
2	AllergiesWithinLastYear	Char	3	Allergies Within last year
3	AlopeciaWithinLastYear	Char	3	Alopecia Hair Loss Within the last year
4	AlphaGlucosidaseInhibitors	Char	2	Alphaglucosidase inhibitors
5	AntibodySampleCollected	Char	3	Antibodies sample collected
6	AsthmaWithinLastYear	Char	3	Asthma within last year
7	BetaBlockers	Char	2	Currently taking any medications Beta Blockers
8	BllodForDNASampleCollected	Char	3	Sample Whole Blood for DNA Sample Collecetd
9	BloodForCellsSampleCollected	Char	3	Sample Whole Blood for cells Sample Collected
10	BloodForRNASampleCollected	Char	3	Sample Whole Blood for RNA Sample Collected
11	CancerWithinLastYear	Char	2	Cancer Within the last year
12	CeliacDiseaseWithinLastYear	Char	3	Celiac Disease Within the last year
13	ColitisOrColonProblemsWithinLa	Char	3	Colitis or colon problems Within the last year
14	CongenitalHeartDiseaseWithinLa	Char	2	Congenital heart disease or heart problems Within the last year
15	ConsenToContinuedStorageOfBloo	Char	3	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
16	Corticosteroids	Char	3	Currently taking any medications Corticosteroids ie prednisone
17	Diphenylhydantoin	Char	2	Currently taking any medications Diphenylhydantoin
18	EpilepsyConvulsionsSeizuresWit	Char	3	Epilepsy convulsions or seizures Within the last year
19	HbA1cSamplesCollected	Char	3	HbA1c sample collected
20	HepatitisOrLiverDiseaseWithinL	Char	2	HepatitisLiver disease Within the last year
21	HighBPwithinLastYear	Char	2	High blood pressure within last year
22	HighCholestrolWithinLastYear	Char	3	High cholestrol within last year
23	ImmunosuppressiveTherapies	Char	3	Currently taking any medications Immunosuppressives or immunomodulatory therapies
24	InfectiousMononucleosisWithinL	Char	3	Infectious mononucleosis Within the last year
25	InflammatoryValveDiseaseWithin	Char	2	Inflammatory Valve Disease within last year
26	LimitedLifeExpectancyOrImmunos	Char	2	Diseases likely to limit life expectancy or lead to use of immunosuppressiveimmunomodulatory therapies within the last year
27	Meglinitides	Char	2	Meglinitides
28	Metformin	Char	2	Metformin
29	MultipleSclerosisWithinLastYea	Char	2	Multiple Sclerosis within last year
30	Niacin	Char	2	Currently taking any medications Niacin
31	OGTTSampleCollected	Char	3	OGTT sample collected
32	OtherAutoimmuneDiseasesWithinL	Char	3	Other autoimmune diseases within last year
33	OtherGlucoseLoweringAgents	Char	2	Other glucose lowering agents
34	ParticipantDiagnosedWithT1D	Char	2	Has the participant been diagnosed with type 1 diabetes T1D

Num	Variable	Type	Len	Label
35	ParticipantPregnant	Char	14	For females of child bearing age potential is the participant currently pregnant
36	ParticipantUsedInsulinOrOtherG	Char	2	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alphaglucoisidase inhibitors meglitinides GLP1 mimetics and
37	PerniciousAnemiaWithinLastYear	Char	2	Pernicious anemia Within the last year
38	PlasmaSampleCollected	Char	3	Sample Plasma Sample Collected
39	PotassiumDepletingDiurectics	Char	2	Currently taking any medications Potassium Depleting Diurectics
40	PsoriasisWithinLastYear	Char	3	Psoriasis Within the last year
41	RheumatologicWithinLastYear	Char	2	Rheumatologic disease Within the last year
42	SerumForProteomicsSampleCollec	Char	3	Sample Serum for Proteomics sample collected
43	SerumMechanisticSerumSampleCol	Char	3	Sample Serum Mechanistic Serum Sample Collected
44	SignedMonitoringConsentProtoco	Char	3	Did this participant previously sign a monitoring consent form for protocol version 15Aug11
45	Thiazolidinediones	Char	2	Thiazolidinediones
46	ThyroidDiseaseWithinLastYear	Char	3	Thyroid disease Within the last year
47	UlcerWithinLastYear	Char	2	Ulcer stomach or duodenal Within the last year
48	VitiligoWithinLastYear	Char	2	Vitiligo Within the last year
49	WholeBloodPBMCPlasmaSampleColl	Char	3	Sample Whole Blood PBMCPlasma Sample Collected
50	Antibodycomment	Char	1	Antibodies Comment
51	BetaBlockersSpecify	Char	1	Currently taking any medications Beta Blockers If YES specify
52	BllodForDNAComment	Char	36	Sample Whole Blood for DNA Comment
53	BloodForCellsComment	Char	51	Sample Whole Blood for cells Comment
54	BloodForRNAComment	Char	51	Sample Whole Blood for RNA comment
55	HbA1cComment	Char	13	HbA1c comment
56	ImmunosuppressiveTherapiesSpec	Char	20	Currently taking any medications Immunosuppressives or immunomodulatory therapies If YES specify
57	OGTTComment	Char	184	OGTT comment
58	OtherAutoimmuneDiseasesSpecify	Char	8	Other autoimmune diseases specify
59	PlasmaComment	Char	51	Sample Plasma Comment
60	PotassiumDepletingDiurecticsSp	Char	1	Currently taking any medications Potassium Depleting Diurectics If YES specify
61	SerumForProteomicsComment	Char	51	Sample Serum for Proteomics Comment
62	SerumMechanisticSerumComment	Char	1	Sample Serum Mechanistic Serum comment
63	SteroidsSpecify	Char	50	Currently taking any medications Steroids if YES specify
64	WholeBloodPBMCPlasmaComment	Char	25	Sample Whole Blood PBMCPlasma comment
65	YESSpecify	Char	45	If YES specify
66	DateSignedNEWInformedConsentFo2	Char	3	Date signed NEW informed consent form Month
67	DateSignedNEWInformedConsentFo	Num	8	Date signed NEW informed consent form Day
68	DateSignedNEWInformedConsentFo3	Num	8	Date signed NEW informed consent form Year
69	Heightcm	Num	8	Collect the following assessments Height in cm

Num	Variable	Type	Len	Label
70	Heightin	Num	8	Collect the following assessments Height in inches
71	SeatedArmBPDiastolic	Num	8	Collect the following assessments Seated arm blood pressure Diastolic
72	SeatedArmBPSystolic	Num	8	Collect the following assessments Seated arm blood pressure systolic
73	SeatedHeartRate	Num	8	Collect the following assessments Seated heart rate
74	SeatedRespiratoryRate	Num	8	Collect the following assessments Seated respiratory rate
75	Weightkg	Num	8	Collect the following assessments Weight in kgs
76	Weightlbs	Num	8	Collect the following assessments Weight in lbs
77	MaskID	Num	8	Participant Mask ID#
78	Visit	Char	100	Visit
79	Date_of_Visit	Num	8	Date of Visit
80	Date_Mechanistic_Sample_Coll	Num	8	Date Mechanistic Sample Collected
81	Date_Samples_Collected	Num	8	Date Samples Collected

Data Set Name: nh07_changeofstatus.sas7bdat

Num	Variable	Type	Len	Label
1	ChangeOfStatusOccuring	Char	98	Change in status that has occurred
2	IsParticipantWillingBeContacte	Char	7	Is the participant still willing to be contacted
3	ParticipantCompletedEntireStud	Char	3	Participant completed entire study
4	ReasonForWithdrawal	Char	45	Record the primary reason for withdrawal
5	WillingToBeContacted	Char	3	Is the subject still willing to be contacted
6	WillingToContinueAfterPregnanc	Char	3	Is the participant willing to continue participation as a Control after completion of pregnancy
7	WithdrewConsentWhy	Char	68	If withdrew consent selected record the reason why
8	ReasonAdverseEventSpecify	Char	106	Reason Adverse Event specify
9	ReasonForWithdrawalOTHER	Char	789	If OTHER Specify
10	ReasonWithdrewConsentSpecify	Char	770	Reason Withdrew Consent specify
11	WithdrewConsentWhyIfOther	Char	189	If withdrew consent selected record the reason why If OTHER specify
12	DateCompletionMM	Char	3	Date of completionMM
13	DateCompletionDD	Num	8	Date of completionDD
14	DateCompletionYYYY	Num	8	Date of completionYYYY
15	PhiX174VisitNumber	Num	8	If PhiX174 Visit ONLY ie Weeks 6 7 8 13 14 16 53 54 58 60 or 62 Record week number
16	MaskID	Num	8	Participant Mask ID#
17	Visit	Char	100	Visit
18	Date_of_Visit	Num	8	Date of Visit
19	Date_at_Change_of_Status	Num	8	Date at Change of Status
20	Date_at_Reactivation	Num	8	Date at Reactivation
21	Date_at_Withdrawal	Num	8	Date at Withdrawal
22	Date_at_Last_Visit	Num	8	If Other, Date of Last Visit
23	Date_at_Pregnancy_Completion	Num	8	Date at Pregnancy Completion

Data Set Name: nh09_followupmissedvisit.sas7bdat

Num	Variable	Type	Len	Label
1	MotherBabyWillingToContinueTak	Char	3	Is the participant motherbaby willing to continue taking the study substance
2	ParticipantAgreeToContinue	Char	3	If Yes did the participant agree to continue in the study
3	ParticipantContacted	Char	3	Was the participant contacted
4	ParticipantExpectedToContinue	Char	3	Is the participant expected to continue with future followup visits
5	ParticipantWillingToContinueMe	Char	1	IF YES Is the participant willing to continue taking the study medication as described by the protocol
6	ReasonForMissedVisit	Char	83	What was the primary reason for the missed visit
7	ReasonForMissedVisitSpecify	Char	665	If Other specify
8	ReasonParticipantMissed	Char	710	Provide additional information about the reason the visit was missed if known
9	MissedVisitInfant	Char	1	Which visit was missed
10	VistMissed	Char	18	Which visit was missed
11	MaskID	Num	8	Participant Mask ID#
12	Visit	Char	100	Visit
13	Date_of_Visit	Num	8	Date of Visit

Data Set Name: nh10_dpt1entry.sas7bdat

Num	Variable	Type	Len	Label
1	AddisonsDiseaseEver	Char	2	Addisons Disease ever
2	AddisonsDiseaseWithinLastYear	Char	2	Addisons Disease Within the last year
3	AllergiesEver	Char	3	Allergies Ever
4	AllergiesWithinLastYear	Char	3	Allergies Within last year
5	AlopeciaEver	Char	2	Alopecia Hair Loss Ever
6	AlopeciaWithinLastYear	Char	2	Alopecia Hair Loss Within the last year
7	AlphaGlucosidaseInhibitors	Char	2	Alphaglucosidase inhibitors
8	AntibodySampleCollected	Char	3	Antibodies sample collected
9	AsthmaEver	Char	3	Asthma ever
10	AsthmaWithinLastYear	Char	3	Asthma within last year
11	BetaBlockers	Char	3	Currently taking any medications Beta Blockers
12	BllodForDNASampleCollected	Char	3	Sample Whole Blood for DNA Sample Collecetd
13	BloodForCellsSampleCollected	Char	3	Sample Whole Blood for cells Sample Collected
14	BloodForRNASampleCollected	Char	3	Sample Whole Blood for RNA Sample Collected
15	CancerEver	Char	2	Cancer Ever
16	CancerWithinLastYear	Char	2	Cancer Within the last year
17	CeliacDiseaseEver	Char	2	Celiac Disease ever
18	CeliacDiseaseWithinLastYear	Char	2	Celiac Disease Within the last year
19	ColitisOrColonProblemsEver	Char	3	Colitis or colon problems ever
20	ColitisOrColonProblemsWithinLa	Char	3	Colitis or colon problems Within the last year
21	CongenitalHeartDiseaseEver	Char	3	Congenital heart disease or heart problems ever
22	CongenitalHeartDiseaseWithinLa	Char	2	Congenital heart disease or heart problems Within the last year
23	ConsenToContinuedStorageOfBloo	Char	3	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
24	Corticosteroids	Char	3	Currently taking any medications Corticosteroids ie prednisone
25	Diphenylhydantoin	Char	3	Currently taking any medications Diphenylhydantoin
26	EpilepsyConvulsionsSeizuresEve	Char	3	Epilepsy convulsions or seizures ever
27	EpilepsyConvulsionsSeizuresWit	Char	3	Epilepsy convulsions or seizures Within the last year
28	Ethnicity	Char	22	Participant Ethnicity
29	HbA1cSamplesCollected	Char	3	HbA1c sample collected
30	HepatitisOrLiverDiseaseEver	Char	2	HepatitisLiver disease ever
31	HepatitisOrLiverDiseaseWithinL	Char	2	HepatitisLiver disease Within the last year
32	HighBPever	Char	3	High blood pressure ever
33	HighBPwithinLastYear	Char	3	High blood pressure within last year
34	HighCholestrolEver	Char	3	High Cholestrol ever
35	HighCholestrolWithinLastYear	Char	3	High cholestrol within last year

Num	Variable	Type	Len	Label
36	ImmunosuppressiveTherapies	Char	2	Currently taking any medications Immunosuppressives or immunomodulatory therapies
37	InfectiousMononucleosisEver	Char	3	Infectious mononucleosis ever
38	InfectiousMononucleosisWithinL	Char	3	Infectious mononucleosis Within the last year
39	InflammatoryValveDiseaseWithin	Char	2	Inflammatory Valve Disease within last year
40	LimitedLifeExpectancyOrImmuno	Char	3	Diseases likely to limit life expectancy or lead to use of immunosuppressiveimmunomodulatory therapies ever
41	LimitedLifeExpectancyOrImmunos	Char	3	Diseases likely to limit life expectancy or lead to use of immunosuppressiveimmunomodulatory therapies within the last year
42	Meglinitides	Char	2	Meglinitides
43	Metformin	Char	2	Metformin
44	MultipleSclerosisWithinLastYea	Char	2	Multiple Sclerosis within last year
45	Niacin	Char	3	Currently taking any medications Niacin
46	OGTTSampleCollected	Char	3	OGTT sample collected
47	OtherAutoimmuneDiseasesWithinL	Char	3	Other autoimmune diseases within last year
48	OtherGlucoseLoweringAgents	Char	2	Other glucose lowering agents
49	ParticipantDiagnosedWithT1D	Char	3	Has the participant been diagnosed with type 1 diabetes T1D
50	ParticipantPregnant	Char	14	For females of child bearing agepotential is the participant currently pregnant
51	ParticipantUsedInsulinOrOtherG	Char	2	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alphaglucoSIDase inhibitors meglitinides GLP1 mimetics and
52	PermissionForSampleStorage	Char	3	Storage of hisher samples for future testing
53	PerniciousAnemiaEver	Char	2	Pernicious anemia ever
54	PerniciousAnemiaWithinLastYear	Char	2	Pernicious anemia Within the last year
55	PlasmaSampleCollected	Char	3	Sample Plasma Sample Collected
56	PotassiumDepletingDiurectics	Char	2	Currently taking any medications Potassium Depleting Diurectics
57	PsoriasisEver	Char	3	Psoriasis ever
58	PsoriasisWithinLastYear	Char	3	Psoriasis Within the last year
59	RheumatologicEver	Char	3	Rheumatologic disease Ever
60	RheumatologicWithinLastYear	Char	3	Rheumatologic disease Within the last year
61	SerumForProteomicsSampleCollec	Char	3	Sample Serum for Proteomics sample collected
62	SerumMechanisticSerumSampleCol	Char	3	Sample Serum Mechanistic Serum Sample Collected
63	Sex	Char	6	Participant Sex
64	Thiazolidinediones	Char	2	Thiazolidinediones
65	ThyroidDiseaseEver	Char	3	Thyroid disease ever
66	ThyroidDiseaseWithinLastYear	Char	3	Thyroid disease Within the last year
67	UlcerEver	Char	3	Ulcer stomach or duodenal ever
68	UlcerWithinLastYear	Char	2	Ulcer stomach or duodenal Within the last year
69	VitiligoEver	Char	3	Vitiligo ever
70	VitiligoWithinLastYear	Char	2	Vitiligo Within the last year

Num	Variable	Type	Len	Label
71	WholeBloodPBMCPlasmaSampleColl	Char	3	Sample Whole Blood PBMCPlasma Sample Collected
72	SexOfRelativeWithT1D1	Char	6	Sex of Relative
73	SexOfRelativeWithT1D2	Char	6	Sex of Relative
74	SexOfRelativeWithT1D3	Char	6	Sex of Relative
75	SexOfRelativeWithT1D4	Char	6	Sex of Relative
76	SexOfRelativeWithT1D5	Char	4	Sex of Relative
77	SexOfRelativeWithT1D6	Char	1	Sex of Relative
78	SexOfRelativeWithT1D7	Char	1	Sex of Relative
79	SexOfRelativeWithT1D8	Char	1	Sex of Relative
80	Antibodycomment	Char	32	Antibodies Comment
81	BetaBlockersSpecify	Char	14	Currently taking any medications Beta Blockers If YES specify
82	BllodForDNAComment	Char	1	Sample Whole Blood for DNA Comment
83	BloodForCellsComment	Char	76	Sample Whole Blood for cells Comment
84	BloodForRNAComment	Char	76	Sample Whole Blood for RNA comment
85	DPT1ParticipantIDNumber	Char	9	Did the participant participate in DPT1 if Yes record the DPT1 participant ID number
86	DiphenylhydantoinSpecify	Char	1	Currently taking any medications Diphenylhydantoin If YES specify
87	HbA1cComment	Char	1	HbA1c comment
88	ImmunosuppressiveTherapiesSpec	Char	1	Currently taking any medications Immunosuppressives or immunomodulatory therapies If YES specify
89	OGTTComment	Char	48	OGTT comment
90	OtherAutoimmuneDiseasesSpecify	Char	37	Other autoimmune diseases specify
91	OtherSpecify	Char	7	Participant Race other specify
92	PlasmaComment	Char	76	Sample Plasma Comment
93	PotassiumDepletingDiurecticsSp	Char	1	Currently taking any medications Potassium Depleting Diurectics If YES specify
94	SerumForProteomicsComment	Char	35	Sample Serum for Proteomics Comment
95	SerumMechanisticSerumComment	Char	1	Sample Serum Mechanistic Serum comment
96	SteroidsSpecify	Char	11	Currently taking any medications Steroids if YES specify
97	WholeBloodPBMCPlasmaComment	Char	1	Sample Whole Blood PBMCPlasma comment
98	YESSpecify	Char	72	If YES specify
99	RelativeComments1	Char	22	Relative Comments
100	RelativeComments2	Char	26	Relative Comments
101	RelativeComments3	Char	12	Relative Comments
102	RelativeComments4	Char	38	Relative Comments
103	RelativeComments5	Char	8	Relative Comments
104	RelativeComments6	Char	1	Relative Comments
105	RelativeComments7	Char	1	Relative Comments
106	RelativeComments8	Char	1	Relative Comments
107	DateSignedNEWInformedConsentFo2	Char	3	Date signed NEW informed consent form Month

Num	Variable	Type	Len	Label
108	RelativeWithT1D1	Char	17	Relative with Type 1 Diabetes
109	RelativeWithT1D2	Char	21	Relative with Type 1 Diabetes
110	RelativeWithT1D3	Char	17	Relative with Type 1 Diabetes
111	RelativeWithT1D4	Char	17	Relative with Type 1 Diabetes
112	RelativeWithT1D5	Char	13	Relative with Type 1 Diabetes
113	RelativeWithT1D6	Char	1	Relative with Type 1 Diabetes
114	RelativeWithT1D7	Char	1	Relative with Type 1 Diabetes
115	RelativeWithT1D8	Char	1	Relative with Type 1 Diabetes
116	DateSignedNEWInformedConsentFo	Num	8	Date signed NEW informed consent form Day
117	DateSignedNEWInformedConsentFo3	Num	8	Date signed NEW informed consent form Year
118	Heightcm	Num	8	Collect the following assessments Height in cm
119	Heightin	Num	8	Collect the following assessments Height in inches
120	NumOfRelativesWithT1D	Num	8	How many of the participants blood relatives have type 1 diabetes including deceased relatives
121	SeatedArmBPDdiastolic	Num	8	Collect the following assessments Seated arm blood pressure Diastolic
122	SeatedArmBPSystolic	Num	8	Collect the following assessments Seated arm blood pressure systolic
123	SeatedHeartRate	Num	8	Collect the following assessments Seated heart rate
124	SeatedRespiratoryRate	Num	8	Collect the following assessments Seated respiratory rate
125	Weightkg	Num	8	Collect the following assessments Weight in kgs
126	Weightlbs	Num	8	Collect the following assessments Weight in lbs
127	AgeOfOnsetInRelativeWithT1D1	Num	8	Age of Onset in Relative
128	AgeOfOnsetInRelativeWithT1D2	Num	8	Age of Onset in Relative
129	AgeOfOnsetInRelativeWithT1D3	Num	8	Age of Onset in Relative
130	AgeOfOnsetInRelativeWithT1D4	Num	8	Age of Onset in Relative
131	AgeOfOnsetInRelativeWithT1D5	Num	8	Age of Onset in Relative
132	AgeOfOnsetInRelativeWithT1D6	Num	8	Age of Onset in Relative
133	AgeOfOnsetInRelativeWithT1D7	Num	8	Age of Onset in Relative
134	AgeOfOnsetInRelativeWithT1D8	Num	8	Age of Onset in Relative
135	AgeOfRelativeWithT1D1	Num	8	Current Age of Relative
136	AgeOfRelativeWithT1D2	Num	8	Current Age of Relative
137	AgeOfRelativeWithT1D3	Num	8	Current Age of Relative
138	AgeOfRelativeWithT1D4	Num	8	Current Age of Relative
139	AgeOfRelativeWithT1D5	Num	8	Current Age of Relative
140	AgeOfRelativeWithT1D6	Num	8	Current Age of Relative
141	AgeOfRelativeWithT1D7	Num	8	Current Age of Relative
142	AgeOfRelativeWithT1D8	Num	8	Current Age of Relative
143	AgeRelativeWithT1DStartedIn1	Num	8	Age Relative Started Insulin
144	AgeRelativeWithT1DStartedIn2	Num	8	Age Relative Started Insulin
145	AgeRelativeWithT1DStartedIn3	Num	8	Age Relative Started Insulin

Num	Variable	Type	Len	Label
146	AgeRelativeWithT1DStartedIn4	Num	8	Age Relative Started Insulin
147	AgeRelativeWithT1DStartedIn5	Num	8	Age Relative Started Insulin
148	AgeRelativeWithT1DStartedIn6	Num	8	Age Relative Started Insulin
149	AgeRelativeWithT1DStartedIn7	Num	8	Age Relative Started Insulin
150	AgeRelativeWithT1DStartedIn8	Num	8	Age Relative Started Insulin
151	Race_AmericanIndianorAlaskaNat	Num	8	Race: American Indian or Alaska Native
152	Race_Asian	Num	8	Race: Asian
153	Race_BlackorAfricanAmerican	Num	8	Race: Black or African American
154	Race_NativeHawaiianorOtherPaci	Num	8	Race: Native Hawaiian or Other Pacific Islander
155	Race_Refused	Num	8	Race: Refused
156	Race_Unknownornotreported	Num	8	Race: Unknown or not reported
157	Race_White	Num	8	Race: White
158	MaskID	Num	8	Participant Mask ID#
159	Visit	Char	100	Visit
160	Date_of_Visit	Num	8	Date of Visit
161	Date_Consent_Signed	Num	8	Date Consent Signed
162	Date_Mechanistic_Sample_Coll	Num	8	Date Mechanistic Sample Collected
163	Date_Samples_Collected	Num	8	Date Samples Collected
164	DOB_Month	Num	8	Date of Birth - Month
165	DOB_Year	Num	8	Date of Birth - Year

Data Set Name: nh12_controlentry.sas7bdat

Num	Variable	Type	Len	Label
1	AddisonsDiseaseEver	Char	2	Addisons Disease ever
2	AddisonsDiseaseWithinLastYear	Char	2	Addisons Disease Within the last year
3	AllergiesEver	Char	3	Allergies Ever
4	AllergiesWithinLastYear	Char	3	Allergies Within last year
5	AlopeciaEver	Char	3	Alopecia Hair Loss Ever
6	AlopeciaWithinLastYear	Char	3	Alopecia Hair Loss Within the last year
7	AlphaGlucosidaseInhibitors	Char	1	Alphaglucosidase inhibitors
8	AntibodySampleCollected	Char	3	Antibodies sample collected
9	AsthmaEver	Char	3	Asthma ever
10	AsthmaWithinLastYear	Char	3	Asthma within last year
11	BetaBlockers	Char	2	Currently taking any medications Beta Blockers
12	BllodForDNASampleCollected	Char	3	Sample Whole Blood for DNA Sample Collecetd
13	BloodForCellsSampleCollected	Char	3	Sample Whole Blood for cells Sample Collected
14	BloodForRNASampleCollected	Char	3	Sample Whole Blood for RNA Sample Collected
15	CancerEver	Char	2	Cancer Ever
16	CancerWithinLastYear	Char	2	Cancer Within the last year
17	CeliacDiseaseEver	Char	3	Celiac Disease ever
18	CeliacDiseaseWithinLastYear	Char	3	Celiac Disease Within the last year
19	ColitisOrColonProblemsEver	Char	3	Colitis or colon problems ever
20	ColitisOrColonProblemsWithinLa	Char	3	Colitis or colon problems Within the last year
21	CongenitalHeartDiseaseEver	Char	3	Congenital heart disease or heart problems ever
22	CongenitalHeartDiseaseWithinLa	Char	2	Congenital heart disease or heart problems Within the last year
23	ConsenToContinuedStorageOfBloo	Char	14	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
24	Corticosteroids	Char	2	Currently taking any medications Corticosteroids ie prednisone
25	Diphenylhydantoin	Char	2	Currently taking any medications Diphenylhydantoin
26	EpilepsyConvulsionsSeizuresEve	Char	2	Epilepsy convulsions or seizures ever
27	EpilepsyConvulsionsSeizuresWit	Char	2	Epilepsy convulsions or seizures Within the last year
28	EverPositiveForDiabetesAntibod	Char	2	Has the participant ever tested positive for diabetes autoantibodies
29	HLASamplesCollected	Char	3	HLA sample collected
30	HbA1cSamplesCollected	Char	3	HbA1c sample collected
31	HepatitisOrLiverDiseaseEver	Char	2	HepatitisLiver disease ever
32	HepatitisOrLiverDiseaseWithinL	Char	2	HepatitisLiver disease Within the last year
33	HighBPever	Char	2	High blood pressure ever
34	HighBPwithinLastYear	Char	2	High blood pressure within last year
35	HighCholestrolEver	Char	3	High Cholestrol ever
36	HighCholestrolWithinLastYear	Char	3	High cholestrol within last year

Num	Variable	Type	Len	Label
37	ImmunosuppressiveTherapies	Char	3	Currently taking any medications Immunosuppressives or immunomodulatory therapies
38	InfectiousMononucleosisEver	Char	3	Infectious mononucleosis ever
39	InfectiousMononucleosisWithinL	Char	2	Infectious mononucleosis Within the last year
40	InflammatoryValveDiseaseEver	Char	2	Inflammatory Valve Disease ever
41	InflammatoryValveDiseaseWithin	Char	2	Inflammatory Valve Disease within last year
42	Meglinitides	Char	1	Meglinitides
43	Metformin	Char	1	Metformin
44	MultipleSclerosisEver	Char	2	Multiple Sclerosis ever
45	MultipleSclerosisWithinLastYea	Char	2	Multiple Sclerosis within last year
46	Niacin	Char	2	Currently taking any medications Niacin
47	OGTTSampleCollected	Char	3	OGTT sample collected
48	OtherAutoimmuneDiseasesEver	Char	2	Other autoimmune diseases ever
49	OtherAutoimmuneDiseasesWithinL	Char	2	Other autoimmune diseases within last year
50	OtherGlucoseLoweringAgents	Char	1	Other glucose lowering agents
51	ParticipantDiagnosedWithT1D	Char	2	Has the participant been diagnosed with type 1 diabetes T1D
52	ParticipantHasKnownSevereActiv	Char	2	Does the participant have known severe inactive diseases and/or diseases which are likely to limit life expectancy or lead to use of immunosuppressive or immunomodulatory therapies during the course of the study
53	ParticipantHasOneRelativeWithT	Char	3	Does the participant have at least one blood relative living or deceased with type 1 diabetes T1D
54	ParticipantPregnant	Char	14	For females of child bearing age/potential is the participant currently pregnant
55	ParticipantUsedInsulinOrOtherG	Char	2	Has the participant ever previously used or is currently using medications for the control of hyperglycemia eg insulin oral hypoglycemic agents including sulfonylureas metformin thiazolidinediones alpha-glucosidase inhibitors meglitinides GLP1 mimetics and
56	ParticipantUsingImmunosuppressi	Char	2	Is the participant currently using immunosuppressive or immunomodulatory therapies or systemic glucocorticoids
57	PerniciousAnemiaEver	Char	2	Pernicious anemia ever
58	PerniciousAnemiaWithinLastYear	Char	2	Pernicious anemia Within the last year
59	PlasmaSampleCollected	Char	3	Sample Plasma Sample Collected
60	PotassiumDepletingDiurectics	Char	2	Currently taking any medications Potassium Depleting Diurectics
61	PsoriasisEver	Char	3	Psoriasis ever
62	PsoriasisWithinLastYear	Char	2	Psoriasis Within the last year
63	RheumatologicEver	Char	3	Rheumatologic disease Ever
64	RheumatologicWithinLastYear	Char	3	Rheumatologic disease Within the last year
65	SerumForProteomicsSampleCollec	Char	3	Sample Serum for Proteomics sample collected
66	SerumMechanisticSerumSampleCol	Char	1	Sample Serum Mechanistic Serum Sample Collected
67	Thiazolidinediones	Char	1	Thiazolidinediones
68	ThyroidDiseaseEver	Char	3	Thyroid disease ever
69	ThyroidDiseaseWithinLastYear	Char	3	Thyroid disease Within the last year

Num	Variable	Type	Len	Label
70	UlcerEver	Char	3	Ulcer stomach or duodenal ever
71	UlcerWithinLastYear	Char	2	Ulcer stomach or duodenal Within the last year
72	VitiligoEver	Char	2	Vitiligo ever
73	VitiligoWithinLastYear	Char	2	Vitiligo Within the last year
74	WholeBloodPBMCPlasmaSampleColl	Char	1	Sample Whole Blood PBMCPlasma Sample Collected
75	Antibodycomment	Char	21	Antibodies Comment
76	BetaBlockersSpecify	Char	1	Currently taking any medications Beta Blockers If YES specify
77	BllodForDNAComment	Char	1	Sample Whole Blood for DNA Comment
78	BloodForCellsComment	Char	1	Sample Whole Blood for cells Comment
79	BloodForRNAComment	Char	1	Sample Whole Blood for RNA comment
80	HLAComment	Char	23	HLA comment
81	HbA1cComment	Char	23	HbA1c comment
82	ImmunosuppressiveTherapiesSpec	Char	39	Currently taking any medications Immunosuppressives or immunomodulatory therapies If YES specify
83	OGTTComment	Char	57	OGTT comment
84	OtherAutoimmuneDiseasesSpecify	Char	1	Other autoimmune diseases specify
85	ParticipantUsedInsulinOrOtherG2	Char	1	If yes specify
86	PlasmaComment	Char	1	Sample Plasma Comment
87	PotassiumDepletingDiurecticsSp	Char	1	Currently taking any medications Potassium Depleting Diurectics If YES specify
88	SerumForProteomicsComment	Char	1	Sample Serum for Proteomics Comment
89	SerumMechanisticSerumComment	Char	1	Sample Serum Mechanistic Serum comment
90	SteroidsSpecify	Char	1	Currently taking any medications Steroids if YES specify
91	WholeBloodPBMCPlasmaComment	Char	1	Sample Whole Blood PBMCPlasma comment
92	YESSpecify	Char	47	If YES specify
93	DateSignedNEWInformedConsentFo2	Char	3	Date signed NEW informed consent form Month
94	DateSignedNEWInformedConsentFo	Num	8	Date signed NEW informed consent form Day
95	DateSignedNEWInformedConsentFo3	Num	8	Date signed NEW informed consent form Year
96	Heightcm	Num	8	Collect the following assessments Height in cm
97	Heightin	Num	8	Collect the following assessments Height in inches
98	SeatedArmBPDiastolic	Num	8	Collect the following assessments Seated arm blood pressure Diastolic
99	SeatedArmBPSystolic	Num	8	Collect the following assessments Seated arm blood pressure systolic
100	SeatedHeartRate	Num	8	Collect the following assessments Seated heart rate
101	SeatedRespiratoryRate	Num	8	Collect the following assessments Seated respiratory rate
102	Weightkg	Num	8	Collect the following assessments Weight in kgs
103	Weightlbs	Num	8	Collect the following assessments Weight in lbs
104	MaskID	Num	8	Participant Mask ID#
105	Visit	Char	100	Visit
106	Date_of_Visit	Num	8	Date of Visit

Num	Variable	Type	Len	Label
107	Date_Consent_Signed	Num	8	Date Consent Signed
108	Date_Mechanistic_Sample_Coll	Num	8	Date Mechanistic Sample Collected
109	Date_Samples_Collected	Num	8	Date Samples Collected

Data Set Name: protocol_deviation.sas7bdat

Num	Variable	Type	Len	Label
1	Deviation	Char	1	Protocol Deviation
2	DeviationError	Char	49	Protocol deviationprocedural error
3	DeviationReportedFor	Char	6	Protocol deviation reported for
4	PInotified	Char	3	Was PI notified
5	ProtocolDeviation	Char	87	Protocol Deviation
6	ProtocolDeviation2	Char	83	Protocol Deviation
7	ProtocolDeviationApprovedByElg	Char	3	Was protocol deviation approved by the Eligibility Committee
8	RequiredBloodCollectionProcedu	Char	1	Required procedureblood collection not completed Specify
9	SubjectRandomizedIneligibilityA	Char	3	If Ineligible subject randomized checked approved by Eligibility Committee
10	TN16ProtocolDeviation	Char	88	TN16 Protocol deviation
11	TestingErrorProcedure	Char	1	Testing procedure error
12	CorrectiveActionTaken	Char	989	Corrective action taken if necessary depending on circumstances
13	DescribeCorrectionAction	Char	175	Describe corrective action taken if neccessary depending on circumstances
14	DescribeDeviation	Char	204	Describe Deviation procedural error and circumstances
15	DeviationCircumstances	Char	3445	Describe deviation and circumstances
16	DeviationOccurenceSpecify	Char	1	IF OTHER Specify Deviation
17	ExlcudedMedicationSpecify	Char	1	Excluded Medications Specify
18	ExplanProtocolDeviation	Char	1	Explanation for protocol deviation
19	IfMiscellaneousSpecify	Char	292	If Miscellaneous specify
20	OtherSpecify	Char	116	Other Specify
21	OtherSpecify2	Char	159	If Other Specify
22	OtherSpecify3	Char	1	Other Specify
23	ProtocolChair	Char	1	If yes who was the protocol chair
24	ProtocolDeviationSpecify	Char	119	If OTHER Specify deviation
25	ProtocolDeviationOtherSubcateg	Char	89	Protocol Deviation Other subcategory
26	StudyVisitCompletedFor	Char	13	Study visit this form being completed for
27	PhiX174WeekNumber	Num	8	If PhiX174 Visit ONLY ie Weeks 6 7 8 13 14 16 53 54 58 59 60 62 Record week number
28	MaskID	Num	8	Participant Mask ID#
29	Visit	Char	100	Visit
30	Date_of_Visit	Num	8	Date of Visit
31	Date_at_Deviation	Num	8	Date at Deviation
32	Date_at_Other	Num	8	Date at Other
33	Date_at_Protocol_Deviation	Num	8	Date at Protocol Deviation

Data Set Name: registration.sas7bdat

Num	Variable	Type	Len	Label
1	status	Char	20	Participant Status
2	MaskID	Num	8	Participant Mask ID#
3	Date_of_Study_Start	Num	8	Date of Study Start
4	Date_of_Registration	Num	8	Date of Registration

Data Set Name: research_labs_baa.sas7bdat

Num	Variable	Type	Len	Label
1	MaskID	Num	8	Participant Mask ID#
2	Date_of_Draw	Num	8	Draw Date
3	Event_Title	Char	100	Form Title
4	SPEC_NAME	Char	250	Sample Name
5	SampleMaskID	Char	10	Sample Mask ID#
6	TEST_NAME	Char	150	Test Name
7	RESULT	Char	1000	Result
8	ResultType	Char	6	
9	Visit	Char	48	Time Point
10	Date_at_Test_Results_Reported	Num	8	
11	Date_at_Evaluation	Num	8	
12	Date_Received	Num	8	
13	Date_Shipped	Num	8	
14	labid	Num	8	INSTITUTION_ID

Data Set Name: research_labs_other.sas7bdat

Num	Variable	Type	Len	Label
1	MaskID	Num	8	Participant Mask ID#
2	Date_of_Draw	Num	8	Draw Date
3	Event_Title	Char	100	Form Title
4	SPEC_NAME	Char	250	Sample Name
5	SampleMaskID	Char	10	Sample Mask ID#
6	TEST_NAME	Char	150	Test Name
7	RESULT	Char	1000	Result
8	ResultType	Char	6	
9	Visit	Char	48	Time Point
10	Date_at_Test_Results_Reported	Num	8	
11	Date_at_Evaluation	Num	8	
12	Date_Received	Num	8	
13	Date_Shipped	Num	8	
14	labid	Num	8	INSTITUTION_ID

Data Set Name: tn01_211746_additiona.sas7bdat

Num	Variable	Type	Len	Label
1	StorageOfResidualsDuringTrialN	Char	14	Did participant consent to current storage of residual blood samples in the NIDDK repository during TrialNets existence
2	WhichProtocolVersion	Char	12	Which version of the Natural History protocol is your site using
3	WhyAccessingParticipantRecord	Char	71	Why are you accessing this participant record
4	_15Aug2011ConsentForResidualSa	Char	7	Did participant consent to continued storage of residual blood samples in the NIDDK Repository after TrialNet has ended
5	_15Aug2011VisitType	Char	37	Visit type
6	_22Jul2009DPT1StorageConsent	Char	1	On the Phase 3 Informed Consent form did the participant give permission for blood samples to be stored for future testing
7	_22Jul2009Phase2HLAConsent	Char	3	On the Phase 2 Informed Consent form did the participant give permission for hisher blood to be tested for HLA genes
8	_22Jul2009Phase2StorageConsent	Char	3	On the Phase 2 Informed Consent form did the participant give permission for storage of hisher samples for future testing
9	_22Jul2009Phase3StorageConsent	Char	3	On the Phase 3 Informed Consent form did the participant give permission for blood samples to be stored for future testing
10	_22Jul2009ScreeningInformedCon	Char	7	Did participant give permission for remaining blood samples to be stored for future testing as described in the informed consent form
11	_22Jul2009VisitType	Char	37	Visit Type
12	_15Aug2011ConsentDateMonth	Char	3	Date Informed Consent signed for 15Aug2011 protocol version month
13	_22Jul2009ConsentSignedMonth	Char	3	Date Informed Consent signed for 22July2009 protocol version month
14	_15Aug2011ConsentDateDay	Num	8	Date Informed Consent signed for 15Aug2011 protocol version day
15	_15Aug2011ConsentDateYear	Num	8	Date Informed Consent signed for 15Aug2011 protocol version year
16	_22Jul2009ConsentSignedDay	Num	8	Date Informed Consent signed for 22July2009 protocol version day
17	_22Jul2009ConsentSignedYear	Num	8	Date Informed Consent signed for 22July2009 protocol version year
18	MaskID	Num	8	Participant Mask ID#
19	Visit	Char	100	Visit
20	Date_of_Visit	Num	8	Date of Visit

Data Set Name: tn01_211857_autoantib.sas7bdat

Num	Variable	Type	Len	Label
1	Followupstatuscode	Char	224	Followup status code check one
2	Followupcomments	Char	791	Followup Comments
3	MaskID	Num	8	Participant Mask ID#
4	Visit	Char	100	Visit
5	Date_of_Visit	Num	8	Date of Visit

Data Set Name: tn01_211858_changeofm.sas7bdat

Num	Variable	Type	Len	Label
1	MonitoringSchedulingChangeEffe2	Char	3	Monitoring Scheduling Changes Date change in schedule became effective Month
2	MonitoringSchedulingChangeSemi	Num	8	Monitoring Scheduling Changes Modify the participant schedule to include semiannual monitoring visits
3	MonitoringSchedulingChangeEffe	Num	8	Monitoring Scheduling Changes Date change in schedule became effective Day
4	MonitoringSchedulingChangeEffe3	Num	8	Monitoring Scheduling Changes Date change in schedule became effective Year
5	MaskID	Num	8	Participant Mask ID#
6	Visit	Char	100	Visit
7	Date_of_Visit	Num	8	Date of Visit

Data Set Name: tn01_212440_nh14ccont.sas7bdat

Num	Variable	Type	Len	Label
1	DoesTheParticipantWishToContin	Char	3	Does the participant wish to continue in the Pathway to Prevention Study as an Ab positive participant
2	WasTheParticipantNotified	Char	3	Was the participant notified of their change in autoantibody positive status
3	DateControlBecameAutoantibodyP2	Char	3	Date control participant became Autoantibody positive month
4	DateControlBecameAutoantibodyP	Num	8	Date control participant became Autoantibody positive day
5	DateControlBecameAutoantibodyP3	Num	8	Date control participant became Autoantibody positive year
6	MaskID	Num	8	Participant Mask ID#
7	Visit	Char	100	Visit
8	Date_of_Visit	Num	8	Date of Visit

Data Set Name: tn_210416_diabetesons.sas7bdat

Num	Variable	Type	Len	Label
1	AnionGapUnits	Char	22	If yes report as many of the following as available Anion Gap Units
2	BicarbonateUnits	Char	22	If yes report as many of the following as available Bicarbonate Units
3	Currentvisitorlastscheduledvis	Char	8	Current visit or last scheduled visit preceding diagnosis of diabetes
4	DiagnosisBy	Char	19	Diagnosis made by
5	Fatigue	Char	3	Did the participant experience fatigue
6	HospitalizedAtDiagnosisTime	Char	3	Was the participant hospitalized at the time of diagnosis
7	Ketoacidosis	Char	3	Did the participant experience Ketoacidosis
8	PlasmaGlucoseUnits	Char	6	If yes report as many of the following as available Plasma Glucose Units
9	Polydipsia	Char	3	Did the participant experience Polydipsia
10	Polyphagia	Char	3	Did the participant experience Polyphagia
11	Polyuria	Char	3	Did the participant experience Polyuria
12	SerumKetonesUnits	Char	7	If yes report as many of the following as available Serum Ketones units
13	UnexperiencedWeightLoss	Char	3	Did the participant experience unexplained weight loss
14	UrineKetonesUnits	Char	7	If yes report as many of the following as available Urine Ketones Units
15	pHUnits	Char	7	If yes report as many of the following as available pHserum Units
16	GlucoseType1	Char	9	Glucose Type
17	GlucoseType2	Char	9	Glucose Type
18	GlucoseType3	Char	9	Glucose Type
19	GlucoseType4	Char	9	Glucose Type
20	GlucoseType5	Char	9	Glucose Type
21	GlucoseType6	Char	9	Glucose Type
22	GlucoseType7	Char	9	Glucose Type
23	GlucoseType8	Char	7	Glucose Type
24	GlucoseType9	Char	6	Glucose Type
25	GlucoseType10	Char	7	Glucose Type
26	GlucoseType11	Char	6	Glucose Type
27	GlucoseType12	Char	6	Glucose Type
28	MeasuredBy1	Char	9	Glucose Levels measured by
29	MeasuredBy2	Char	9	Glucose Levels measured by
30	MeasuredBy3	Char	9	Glucose Levels measured by
31	MeasuredBy4	Char	9	Glucose Levels measured by
32	MeasuredBy5	Char	9	Glucose Levels measured by
33	MeasuredBy6	Char	9	Glucose Levels measured by
34	MeasuredBy7	Char	9	Glucose Levels measured by
35	MeasuredBy8	Char	9	Glucose Levels measured by
36	MeasuredBy9	Char	9	Glucose Levels measured by

Num	Variable	Type	Len	Label
37	MeasuredBy10	Char	9	Glucose Levels measured by
38	MeasuredBy11	Char	9	Glucose Levels measured by
39	MeasuredBy12	Char	9	Glucose Levels measured by
40	Units1	Char	6	Glucose level Units
41	Units2	Char	6	Glucose level Units
42	Units3	Char	6	Glucose level Units
43	Units4	Char	6	Glucose level Units
44	Units5	Char	6	Glucose level Units
45	Units6	Char	6	Glucose level Units
46	Units7	Char	6	Glucose level Units
47	Units8	Char	6	Glucose level Units
48	Units9	Char	6	Glucose level Units
49	Units10	Char	6	Glucose level Units
50	Units11	Char	6	Glucose level Units
51	Units12	Char	1	Glucose level Units
52	DiagnosisByOthersSpecify	Char	97	If other facility specify
53	DateInsulinTreatmentStartedUnk	Num	8	Date Insulin treatment started Unknown
54	AnionGapRefRangeHigh	Num	8	If yes report as many of the following as available Anion Gap Higher reference range
55	AnionGapRefRangeLow	Num	8	If yes report as many of the following as available Anion Gap Lower reference range
56	AnionGapResult	Num	8	If yes report as many of the following as available Anion Gap Result
57	BicarbonateRefRangeHigh	Num	8	If yes report as many of the following as available Bicarbonate Higher reference range
58	BicarbonateRefRangeLow	Num	8	If yes report as many of the following as available Bicarbonate Lower reference range
59	BicarbonateResult	Num	8	If yes report as many of the following as available Bicarbonate Result
60	HbA1cLowerReferenceRange	Num	8	Other laboratory values HbA1c Lower Reference Range
61	HbA1cResult	Num	8	Other laboratory values HbA1c Result
62	HbA1chigherrReferenceRange	Num	8	Other laboratory values HbA1c Higher Reference Range
63	PlasmaGlucoseRefRangeHigh	Num	8	If yes report as many of the following as available Plasma Glucose High reference range
64	PlasmaGlucoseRefRangeLow	Num	8	If yes report as many of the following as available Plasma Glucose Low reference range
65	PlasmaGlucoseResult	Num	8	If yes report as many of the following as available Plasma Glucose Result
66	SerumKetonesRefRangeHigh	Num	8	If yes report as many of the following as available Serum Ketones Higher reference range
67	SerumKetonesRefRangeLow	Num	8	If yes report as many of the following as available Serum Ketones Loer reference range
68	SerumKetonesResult	Num	8	If yes report as many of the following as available Serum Ketones Result
69	UrineKetonesRefRangeHigh	Num	8	If yes report as many of the following as available Urine Ketones Higher reference range

Num	Variable	Type	Len	Label
70	UrineKetonesRefRangeLow	Num	8	If yes report as many of the following as available Urine Ketones Lower reference range
71	UrineKetonesResult	Num	8	If yes report as many of the following as available Urine Ketones Result
72	WeightLostInKgs	Num	8	If YES amount of weight lost in Kgs
73	WeightLostInLbs	Num	8	If YES amount of weight lost in Lbs
74	pHReferenceRangeHigh	Num	8	If yes report as many of the following as available pHserum HigherReference range
75	pHReferenceRangeLow	Num	8	If yes report as many of the following as available pHserum Lower Reference range
76	pHResult	Num	8	If yes report as many of the following as available pHserum Result
77	HigherReferenceRange1	Num	8	Glucose level Higher Reference Range
78	HigherReferenceRange2	Num	8	Glucose level Higher Reference Range
79	HigherReferenceRange3	Num	8	Glucose level Higher Reference Range
80	HigherReferenceRange4	Num	8	Glucose level Higher Reference Range
81	HigherReferenceRange5	Num	8	Glucose level Higher Reference Range
82	HigherReferenceRange6	Num	8	Glucose level Higher Reference Range
83	HigherReferenceRange7	Num	8	Glucose level Higher Reference Range
84	HigherReferenceRange8	Num	8	Glucose level Higher Reference Range
85	HigherReferenceRange9	Num	8	Glucose level Higher Reference Range
86	HigherReferenceRange10	Num	8	Glucose level Higher Reference Range
87	HigherReferenceRange11	Num	8	Glucose level Higher Reference Range
88	HigherReferenceRange12	Num	8	Glucose level Higher Reference Range
89	LowerReferenceRange1	Num	8	Glucose level Lower Reference Range
90	LowerReferenceRange2	Num	8	Glucose level Lower Reference Range
91	LowerReferenceRange3	Num	8	Glucose level Lower Reference Range
92	LowerReferenceRange4	Num	8	Glucose level Lower Reference Range
93	LowerReferenceRange5	Num	8	Glucose level Lower Reference Range
94	LowerReferenceRange6	Num	8	Glucose level Lower Reference Range
95	LowerReferenceRange7	Num	8	Glucose level Lower Reference Range
96	LowerReferenceRange8	Num	8	Glucose level Lower Reference Range
97	LowerReferenceRange9	Num	8	Glucose level Lower Reference Range
98	LowerReferenceRange10	Num	8	Glucose level Lower Reference Range
99	LowerReferenceRange11	Num	8	Glucose level Lower Reference Range
100	LowerReferenceRange12	Num	8	Glucose level Lower Reference Range
101	Result1	Num	8	Glucose level Result
102	Result2	Num	8	Glucose level Result
103	Result3	Num	8	Glucose level Result
104	Result4	Num	8	Glucose level Result
105	Result5	Num	8	Glucose level Result
106	Result6	Num	8	Glucose level Result
107	Result7	Num	8	Glucose level Result

Num	Variable	Type	Len	Label
108	Result8	Num	8	Glucose level Result
109	Result9	Num	8	Glucose level Result
110	Result10	Num	8	Glucose level Result
111	Result11	Num	8	Glucose level Result
112	Result12	Num	8	Glucose level Result
113	MaskID	Num	8	Participant Mask ID#
114	Visit	Char	100	Visit
115	Date_of_Visit	Num	8	Date of Visit
116	Date_at_Hospitalization	Num	8	Date at Hospitalization
117	Date_at_Anion_Gap	Num	8	Date at Anion Gap
118	Date_at_Bicarbonate	Num	8	Date at Bicarbonate
119	Date_at_Diagnosis	Num	8	Date at Diagnosis
120	Date_at_Discharge	Num	8	Date at Discharge
121	Date_at_Fatigue	Num	8	Date at Fatigue
122	Date_at_Glucose1	Num	8	Date at Glucose #1
123	Date_at_Glucose2	Num	8	Date at Glucose #2
124	Date_at_Glucose3	Num	8	Date at Glucose #3
125	Date_at_Glucose4	Num	8	Date at Glucose #4
126	Date_at_Glucose5	Num	8	Date at Glucose #5
127	Date_at_Glucose6	Num	8	Date at Glucose #6
128	Date_at_Glucose7	Num	8	Date at Glucose #7
129	Date_at_Glucose8	Num	8	Date at Glucose #8
130	Date_at_Glucose9	Num	8	Date at Glucose #9
131	Date_at_Glucose10	Num	8	Date at Glucose #10
132	Date_at_Glucose11	Num	8	Date at Glucose #11
133	Date_at_Glucose12	Num	8	Date at Glucose #12
134	Date_at_HbA1c	Num	8	Date at HbA1c
135	Date_at_Insulin_Trtr_Start	Num	8	Date at Insulin Treatment Start
136	Date_at_Plasma_Glucose	Num	8	Date at Plasma Glucose
137	Date_at_Polydipsia	Num	8	Date at Polydipsia
138	Date_at_Polyphagia	Num	8	Date at Polyphagia
139	Date_at_Polyuria	Num	8	Date at Polyuria
140	Date_at_Serum_Ketones	Num	8	Date at Serum Ketones
141	Date_at_Weight_Loss	Num	8	Date at Weight Loss
142	Date_at_Urine_Ketones	Num	8	Date at Urine Ketones
143	Date_at_pH	Num	8	Date at pH

Data Set Name: tn_212619_followupofe.sas7bdat

Num	Variable	Type	Len	Label
1	LONG_DESCRIPTION	Char	18	LONG_DESCRIPTION
2	SHORT_DESCRIPTION	Char	18	SHORT_DESCRIPTION
3	revised_short_desc_checkbox	Char	31	
4	revised_long_description	Char	16	
5	Didtheparticipantindicatetheym	Char	14	Did the participant indicate they may be willing to consider participating in the study at a later time 2
6	Havetherebeenanychangesinthepa	Char	14	Have there been any changes in the participants information since your last contact
7	IndicateTheStudyParticipantWas	Char	35	Please indicate which TrialNet Study this participant was offered
8	Istheparticipantinterestedinth	Char	17	Is the participant interested in the study selected in question 1
9	Participantisahotleadwarmlead	Char	9	Please indicate if the participant is a hot lead warm lead or not eligible
10	Pleaseselecttypeofcontactattem	Char	26	Please select type of contactcontact attempt
11	TN10Exclusion25bDoesthiscondit	Char	3	TN10 Exclusion 25b Does this condition permanently exclude the participant
12	TN16TN19TN20EligibilityStatus	Char	20	TN16 TN19 TN20 Eligibility Status
13	TN18Exclusion12bDoesthiscondit	Char	3	TN18 Exclusion 12b Does this condition permanently exclude the participant
14	TN19Exclusion17bDoesthiscondit	Char	1	TN19 Exclusion 17b Does this condition permanently exclude the participant
15	TN20Exclusion10bDoesthiscondit	Char	1	TN20 Exclusion 10b Does this condition permanently exclude the participant
16	_2bPleaseselecttypeofcontactat	Char	6	2b Please select type of contact attempt
17	FinalContactAttempt1	Char	3	Final Contact Attempt
18	AdditionalComments	Char	585	Additional comments describing participants Situation
19	TN10Exclusion25aPleasespecify	Char	49	TN10 Exclusion 25a Please specify
20	TN18Exclusion12aPleasespecify	Char	40	TN18 Exclusion 12a Please specify
21	TN19Exclusion17aPleasespecify	Char	1	TN19 Exclusion 17a Please specify
22	TN20Exclusion10aPleasespecify	Char	1	TN20 Exclusion 10a Please specify
23	_2aPleaseselecttypeofcontactat	Char	218	2a Please select type of contact attempt other
24	_2bPleaseselecttypeofcontactat2	Char	132	2b Please select type of contact attempt other
25	MethodofContactAttemptOther1	Char	91	Method of Contact Attempt Other
26	ParticipantWasContactedByOt1	Char	58	Participant was contacted by Other Specify
27	DateParticipantwascontacted1_2	Char	3	Date Participant was contacted month
28	code_group_id	Num	8	CODE_GROUP_ID
29	CODE_ID	Num	8	CODE_ID
30	DISPLAY_ORDER	Num	8	DISPLAY_ORDER
31	EFFECTIVE_DATE	Num	8	EFFECTIVE_DATE
32	TERMINATION_DATE	Num	8	TERMINATION_DATE

Num	Variable	Type	Len	Label
33	Participantisnoteligible	Num	8	Please indicate if the participant is not eligible
34	DateParticipantwascontacted1_1	Num	8	Date Participant was contacted day
35	DateParticipantwascontacted1_3	Num	8	Date Participant was contacted year
36	ReasonsNotInterested_2DayInfusio	Num	8	ReasonsNotInterested: 2 Day Infusion Period
37	ReasonsNotInterested_2weekInfusi	Num	8	ReasonsNotInterested: 2 week Infusion Period
38	ReasonsNotInterested_BiweeklyInj	Num	8	ReasonsNotInterested: Biweekly Injection Visit Schedule
39	ReasonsNotInterested_Concernsabo	Num	8	ReasonsNotInterested: Concerns about receiving placebo
40	ReasonsNotInterested_Conflicting	Num	8	ReasonsNotInterested: Conflicting Responsibilities (Work, School, Family)
41	ReasonsNotInterested_Doesnotwant	Num	8	ReasonsNotInterested: Does not want to be blinded to individual test results during the study
42	ReasonsNotInterested_Familywithe	Num	8	ReasonsNotInterested: Family wishes to wait until participant is older
43	ReasonsNotInterested_FearofStudy	Num	8	ReasonsNotInterested: Fear of Study Drug Risks
44	ReasonsNotInterested_LosttoFollo	Num	8	ReasonsNotInterested: Lost to Follow-Up
45	ReasonsNotInterested_MonetaryCom	Num	8	ReasonsNotInterested: Monetary Compensation
46	ReasonsNotInterested_MonthlyInfu	Num	8	ReasonsNotInterested: Monthly Infusion Visit Schedule
47	ReasonsNotInterested_Other	Num	8	ReasonsNotInterested: Other
48	ReasonsNotInterested_Participant	Num	8	ReasonsNotInterested: Participant does not tolerate OGTT/IVGTTs well
49	ReasonsNotInterested_Pregnantnur	Num	8	ReasonsNotInterested: Pregnant, nursing or planning children in the future
50	ReasonsNotInterested_Refusednore	Num	8	ReasonsNotInterested: Refused; no reason given
51	ReasonsNotInterested_TimeCommitm	Num	8	ReasonsNotInterested: Time Commitment
52	ReasonsNotInterested_UnableUnwil	Num	8	ReasonsNotInterested: Unable/ Unwilling to Travel
53	ReasonsNotInterested_Unwillingto	Num	8	ReasonsNotInterested: Unwilling to take investigational drug
54	TN16Exclusion_1Bedeemedunableoru	Num	8	TN16Exclusion: 1. Be deemed unable or unlikely to comply with the protocol
55	_2cTN10Exclusion_10Chronicactive	Num	8	2cTN10Exclusion: 10. Chronic active infection other than localized skin infections
56	_2cTN10Exclusion_11ApositivePPDt	Num	8	2cTN10Exclusion: 11. A positive PPD test
57	_2cTN10Exclusion_12Vaccinationwi	Num	8	2cTN10Exclusion: 12. Vaccination with a live virus within 8 weeks of randomization
58	_2cTN10Exclusion_13Vaccinationwi	Num	8	2cTN10Exclusion: 13. Vaccination with a killed virus within 4 weeks of randomization
59	_2cTN10Exclusion_14Ahistoryofinf	Num	8	2cTN10Exclusion: 14. A history of infectious mononucleosis within the 3 months prior to enrollment
60	_2cTN10Exclusion_15Laboratoryorc	Num	8	2cTN10Exclusion: 15. Laboratory or clinical evidence of acute infection with EBV or CMV
61	_2cTN10Exclusion_16Serologicalev	Num	8	2cTN10Exclusion: 16. Serological evidence of current or past HIV, Hepatitis B or Hepatitis C infection
62	_2cTN10Exclusion_17Becurrentlypr	Num	8	2cTN10Exclusion: 17. Be currently pregnant or lactating, or anticipate getting pregnant
63	_2cTN10Exclusion_18Chronicuseofs	Num	8	2cTN10Exclusion: 18. Chronic use of steroids or other immunosuppressive agents

Num	Variable	Type	Len	Label
64	_2cTN10Exclusion_19Ahistoryofast	Num	8	2cTN10Exclusion: 19. A history of asthma or atopic disease requiring chronic treatment
65	_2cTN10Exclusion_1If18yoDiabete1	Num	8	2cTN10Exclusion: 1. If ?18yo: Diabetes, or have a screening OGTT with: a. Fasting plasma glucose ?126 mg/dL
66	_2cTN10Exclusion_1If18yoDiabete2	Num	8	2cTN10Exclusion: 1. If ?18yo: Diabetes, or have a screening OGTT with: b. 2 hour plasma glucose ? 200mg/dL
67	_2cTN10Exclusion_20Untreatedhypo	Num	8	2cTN10Exclusion: 20. Untreated hypothyroidism or active Graves? disease at randomization
68	_2cTN10Exclusion_21Currentuseofn	Num	8	2cTN10Exclusion: 21. Current use of non-insulin pharmaceuticals that affect glycemic control
69	_2cTN10Exclusion_22PriorOKT3orot	Num	8	2cTN10Exclusion: 22. Prior OKT?3 or other anti-CD3 treatment
70	_2cTN10Exclusion_23Administratio	Num	8	2cTN10Exclusion: 23. Administration of a monoclonal antibody within the year before randomization
71	_2cTN10Exclusion_24Participation	Num	8	2cTN10Exclusion: 24. Participation in any type of therapeutic drug or vaccine clinical trial within the 12 weeks before randomization
72	_2cTN10Exclusion_25Anyconditiont	Num	8	2cTN10Exclusion: 25. Any condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the subject
73	_2cTN10Exclusion_2If18yoDiabetes	Num	8	2cTN10Exclusion: 2. If <18yo: Diabetes, or have a screening random glucose ?200mg/dL
74	_2cTN10Exclusion_3Lymphopenia100	Num	8	2cTN10Exclusion: 3. Lymphopenia (< 1000 lymphocytes/?L)
75	_2cTN10Exclusion_4Neutropenia150	Num	8	2cTN10Exclusion: 4. Neutropenia (< 1500 PMN/?L)
76	_2cTN10Exclusion_5Thrombocytopen	Num	8	2cTN10Exclusion: 5. Thrombocytopenia (< 150,000 platelets/?L)
77	_2cTN10Exclusion_6AnemiaHgb10gra	Num	8	2cTN10Exclusion: 6. Anemia (Hgb < 10 grams/deciliter [g/dL])
78	_2cTN10Exclusion_7ASTorALT15xULN	Num	8	2cTN10Exclusion: 7. AST or ALT >1.5 x ULN
79	_2cTN10Exclusion_8Totalbilirubin	Num	8	2cTN10Exclusion: 8. Total bilirubin >1.5 x upper limit of normal (ULN) with the exception of subjects with the diagnosis of Gilbert?s syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia
80	_2cTN10Exclusion_9INR01abovetheu	Num	8	2cTN10Exclusion: 9. INR > 0.1 above the upper limit of normal at the participating center?s laboratory
81	_2cTN18Exclusion_10Haveserologic	Num	8	2cTN18Exclusion: 10. Have serological evidence of current CMV infection
82	_2cTN18Exclusion_11Haveevidenceo	Num	8	2cTN18Exclusion: 11. Have evidence of active EBV infection
83	_2cTN18Exclusion_12Haveanycompli	Num	8	2cTN18Exclusion: 12. Have any complicating medical issues or abnormal clinical laboratory results
84	_2cTN18Exclusion_13Haveahistoryo	Num	8	2cTN18Exclusion: 13. Have a history of malignancies
85	_2cTN18Exclusion_14HaveMultipleS	Num	8	2cTN18Exclusion: 14. Have Multiple Sclerosis
86	_2cTN18Exclusion_1aAbnormalGluc1	Num	8	2cTN18Exclusion: 1a. Abnormal Glucose Tolerance or Diabetes (43,44) Fasting plasma glucose ? 110 mg/dL (6.1 mmol/L)
87	_2cTN18Exclusion_1aAbnormalGluc2	Num	8	2cTN18Exclusion: 1a. Abnormal Glucose Tolerance or Diabetes (43,44) 2 hour plasma glucose ? 140 mg/dL (7.8 mmol/L)
88	_2cTN18Exclusion_1aAbnormalGluc3	Num	8	2cTN18Exclusion: 1a. Abnormal Glucose Tolerance or Diabetes (43,44) 30, 60, 90 minute plasma glucose during OGTT ? 200 mg/dL (11.1 mmol/L)
89	_2cTN18Exclusion_2Insulinautoant	Num	8	2cTN18Exclusion: 2. Insulin autoantibodies (mIAA)

Num	Variable	Type	Len	Label
90	_2cTN18Exclusion_3Immunodeficient	Num	8	2cTN18Exclusion: 3. Immunodeficient or have clinically significant chronic lymphopenia
91	_2cTN18Exclusion_4Haveanactivein	Num	8	2cTN18Exclusion: 4. Have an active infection at time of randomization
92	_2cTN18Exclusion_5HaveapositiveP	Num	8	2cTN18Exclusion: 5. Have a positive PPD test result or history of previously treated TB, or positive interferon-gamma release assay (IGRA) test.
93	_2cTN18Exclusion_6Becurrentlypre	Num	8	2cTN18Exclusion: 6. Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of the last study drug administration
94	_2cTN18Exclusion_7Useofmedicatio	Num	8	2cTN18Exclusion: 7. Use of medications known to influence glucose tolerance
95	_2cTN18Exclusion_8Requireuseofot	Num	8	2cTN18Exclusion: 8. Require use of other immunosuppressive agents
96	_2cTN18Exclusion_9Haveserologic	Num	8	2cTN18Exclusion: 9. Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B core antibody or surface antigen), or Hepatitis C infection
97	_2cTN19Exclusion_10Evidenceofren	Num	8	2cTN19Exclusion: 10. Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal
98	_2cTN19Exclusion_11Vaccinationwi	Num	8	2cTN19Exclusion: 11. Vaccination with a live virus within the last 6 weeks
99	_2cTN19Exclusion_12Currentorongo	Num	8	2cTN19Exclusion: 12. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening
100	_2cTN19Exclusion_13Activepartici	Num	8	2cTN19Exclusion: 13. Active participation in another T1D treatment study in the previous 30 days
101	_2cTN19Exclusion_14Priortreatmen	Num	8	2cTN19Exclusion: 14. Prior treatment with abatacept or anti-cd3
102	_2cTN19Exclusion_15Knownallergyt	Num	8	2cTN19Exclusion: 15. Known allergy to GCSF or ATG
103	_2cTN19Exclusion_16Priortreatmen	Num	8	2cTN19Exclusion: 16. Prior treatment with ATG or known allergy to rabbit derived products
104	_2cTN19Exclusion_17Anyconditiont	Num	8	2cTN19Exclusion: 17. Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results
105	_2cTN19Exclusion_1Beimmunodefici	Num	8	2cTN19Exclusion: 1. Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia (< 3,000 leukocytes /?L), neutropenia (<1,500 neutrophils/?L), lymphopenia (<800 lymphocytes/?L), or thrombocytopenia (<100,000 platelets/?L)
106	_2cTN19Exclusion_2Haveactivesign	Num	8	2cTN19Exclusion: 2. Have active signs or symptoms of acute infection at the time of randomization
107	_2cTN19Exclusion_3Haveevidenceof	Num	8	2cTN19Exclusion: 3. Have evidence of prior or current tuberculosis infection as assessed by PPD, interferon gamma release assay or by history
108	_2cTN19Exclusion_4Becurrentlypre	Num	8	2cTN19Exclusion: 4. Be currently pregnant or lactating, or anticipate getting pregnant within the two year study period
109	_2cTN19Exclusion_5Requireuseofot	Num	8	2cTN19Exclusion: 5. Require use of other immunosuppressive agents including chronic use of systemic steroids
110	_2cTN19Exclusion_6Haveevidenceof	Num	8	2cTN19Exclusion: 6. Have evidence of current or past HIV, Hepatitis B or Hepatitis C infection
111	_2cTN19Exclusion_7Haveanycomplic	Num	8	2cTN19Exclusion: 7. Have any complicating medical issues or abnormal clinical laboratory results
112	_2cTN19Exclusion_8Haveahistoryof	Num	8	2cTN19Exclusion: 8. Have a history of malignancies other than skin

Num	Variable	Type	Len	Label
113	_2cTN19Exclusion_9Evidenceoflive	Num	8	2cTN19Exclusion: 9. Evidence of liver dysfunction with AST or ALT greater than 3 times the upper limits of normal
114	_2cTN20Exclusion_10Deemedunlikel	Num	8	2cTN20Exclusion: 10. Deemed unlikely or unable to comply with the protocol or have any complicating medical issues or abnormal clinical laboratory results that interfere with study conduct or cause increased risk
115	_2cTN20Exclusion_1DiagnosedwithD	Num	8	2cTN20Exclusion: 1. Diagnosed with Diabetes or having their most recent OGTT with fasting glucose ?126 mg/dl or 2 hour glucose ? 200 mg/dl
116	_2cTN20Exclusion_2Priorparticipa	Num	8	2cTN20Exclusion: 2. Prior participation in clinical research for secondary prevention of T1D
117	_2cTN20Exclusion_3Historyoftreat	Num	8	2cTN20Exclusion: 3. History of treatment with insulin or oral hypoglycemic agent
118	_2cTN20Exclusion_4Currentchronic	Num	8	2cTN20Exclusion: 4. Current chronic use of medications altering stomach acid (such as H2 blockers, proton pump inhibitors and antacids)
119	_2cTN20Exclusion_5Historyofgastr	Num	8	2cTN20Exclusion: 5. History of gastric ulcer or gastric surgery
120	_2cTN20Exclusion_6Historyofthera	Num	8	2cTN20Exclusion: 6. History of therapy with immunosuppressive drugs or non-physiologic glucocorticoids within the past two years for a period of more than three months
121	_2cTN20Exclusion_7Hassevereactiv	Num	8	2cTN20Exclusion: 7. Has severe active disease, e.g. chronic active hepatitis, severe cardiac, pulmonary, renal, hepatic, immune deficiency
122	_2cTN20Exclusion_8Ongoinguseofme	Num	8	2cTN20Exclusion: 8. Ongoing use of medications known to influence glucose tolerance
123	_2cTN20Exclusion_9Pregnantintend	Num	8	2cTN20Exclusion: 9. Pregnant, intends to become pregnant while on study, or lactating
124	MethodofContactA_Email1	Num	8	MethodofContactA: Email
125	MethodofContactA_Mail1	Num	8	MethodofContactA: Mail
126	MethodofContactA_Other1	Num	8	MethodofContactA: Other
127	MethodofContactA_Telephone1	Num	8	MethodofContactA: Telephone
128	ParticipantWasCo_AffiliateSi1_1	Num	8	ParticipantWasCo: Affiliate Site Coordinator
129	ParticipantWasCo_AffiliateSi1_2	Num	8	ParticipantWasCo: Affiliate Site PI
130	ParticipantWasCo_ClinicalCen1_1	Num	8	ParticipantWasCo: Clinical Center Coordinator
131	ParticipantWasCo_ClinicalCen1_2	Num	8	ParticipantWasCo: Clinical Center PI
132	ParticipantWasCo_Other1	Num	8	ParticipantWasCo: Other
133	MaskID	Num	8	Participant Mask ID#
134	Visit	Char	100	Visit
135	Date_of_Visit	Num	8	Date of Visit